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ABSTRACT 
VIVIAN SUSAN CHEN:  Immune Mediators of Central Nervous System Demyelination and 
Remyelination 
(Under the direction of Glenn K. Matsushima) 
 
The principal goal of an immune response is to protect the host from pathogens, 
maintain tissue homeostasis and/or to repair damaged tissue.  However, an inappropriate or 
prolonged immune response may be detrimental.  Neuroinflammation is an integral 
component of demyelinating disease, such as multiple sclerosis, and often leads to 
oligodendrocyte damage and depletion.  Here, we report on two immune mediators, 
interleukin-1 (IL-1) and lymphocyte activation gene-3 (LAG-3, CD223), and their role in 
demyelination and recovery.   
IL-1 can be clinically beneficial or detrimental in human diseases.    In this study, we 
examined the individual roles of IL-1α and IL-1β and their effects on myelination and 
cellular populations during neurodegeneration and recovery.  After extensive backcrossing of 
IL-1α-/-, IL-1β-/-, and IL-1α-/-β-/- mice onto the C57BL/6 background, we demonstrate that IL-
1α and IL-1β do not exacerbate cuprizone-induced demyelination and do not contribute to 
subsequent remyelination.  However, an interesting phenotype emerged in which IL-1β-/- and 
IL-1α-/-β-/- mice show reduced numbers of mature oligodendrocytes in the corpus callosum, 
before and after cuprizone treatment. 
LAG-3 is a membrane-bound glycoprotein that is involved in negative regulation of T 
cell activity and clonal expansion through its interaction with major histocompatibility 
complex class II (MHCII).  Our study is the first to demonstrate upregulation of LAG-3 gene 
and protein expression during demyelination.  Furthermore, LAG-3 gene expression 
coincides with MHCII gene upregulation within the demyelinating lesion.  We also 
demonstrate LAG-3 expression is localized to immature oligodendrocyte progenitor cells 
(OPCs) and astrocytes.  Analyses of LAG-3-/- mice exposed to cuprizone showed an 
increased depletion of mature oligodendrocytes and an accelerated rate of demyelination.  
However, OPCs and astrocytes, as well as microglia/macrophages, responded robustly, and 
during repair, there was a greater number of differentiating mature oligodendrocytes even 
though remyelination appeared normal.  Thus, we have found two novel observations: LAG-
3 is expressed on OPCs and astrocytes, and LAG-3 appears to negatively regulate OPCs 
during remyelination.    
These studies suggest that IL-1β and LAG-3 may have significant regulatory effects 
on glial populations in the central nervous system.  Furthermore, the presence of LAG-3 and 
MHCII in the demyelinating lesion suggests that a direct interaction of OPCs and microglia 
is plausible. 
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INTRODUCTION 
 
 
1.1 Immune Responses in the Central Nervous System 
 
Neuroinflammation is often implicated in the progressive nature of neurodegeneration in 
diseases, such as Alzheimer's disease, Parkinson’s disease, multiple sclerosis (MS), prion 
diseases, and HIV-associated dementia.  Immune responses in the central nervous system 
(CNS) are uniquely dissimilar to that in the peripheral nervous system (PNS) and other 
physiological systems when challenged by injury and infection.  Because neuronal 
maintenance is essential to CNS integrity, the CNS has developed anatomical and 
physiological mechanisms that limit vulnerability to irreversible damage caused by immune 
reactions.  Early observations led to characterizing the CNS as “immune-privileged”: 
allograft survival within the brain parenchyma, the absence of typical lymphatic drainage, the 
presence of a blood-brain barrier (BBB), and the reduced expression of major 
histocompatibility complex class I (MHCI) and MHCII antigens [1].  Furthermore, the CNS 
is protected physically by the dura mater that restricts blunt trauma and invasive injuries, as 
well as limits swelling and edema, and by cerebrospinal fluid, which reduces injury from 
gravitational, rotational, and acceleratory forces [2].  Since these initial findings, the last few 
decades of research have challenged the concept of the CNS as an immune-privileged site.   
It is now accepted that immune T cells, B cells, and monocyte-derived cells monitor the 
CNS in the absence of neuropathology and mount an immune response in the face of insult 
[3].    In relevance to this dissertation, key cellular players of the CNS immune response and 
their participation in homeostasis, neuroinflammation, and repair will be discussed below. 
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Microglia/macrophages.  In the milieu of infection, injury, or disease in any tissue, resident 
macrophage activation is one of the first observable immune responses.  This is no exception 
in the CNS.  The largest population of macrophage-like cells in the brain, comprising 10-
20% of total glial cells, is parenchymal microglia, otherwise known as resident microglia [4-
6].  Studies during fetal development demonstrate that microglial “precursors” migrate in a 
single influx, largely guided by intercellular adhesion molecule-1 (ICAM-1, CD54) and/or 
ICAM-2 expression on cerebral endothelium and lymphocyte function-associated antigen-1 
(LFA-1, CD11a) expression on the colonizing monocytes, to set up residence in the brain [7, 
8].  These cells are exceptionally long-lived and are replaced from the bone marrow in less 
than a few percent per year [9-11].  In a normal physiological state, microglia initially take 
on an ameboid form during migration into the CNS and transition into a ramified form in the 
grey matter, a more longitudinally branched form in the white matter, and a compact form 
that resembles classical macrophages in the periventricular regions [4, 5].  Resident microglia 
remain downregulated in the absence of insult, partly due to constitutive transforming growth 
factor-β (TGFβ) expression in the brain, and are characterized by lack of endocytic and 
phagocytic activity, low expression of the leukocyte common antigen (CD45) and 
CD18/CD11b (Mac-1), and undetectable levels of MHCI and MHCII (reviewed in [4, 12]).  
Aside from immune surveillance, auxiliary functions of microglia in the normal CNS remain 
elusive.  They may play a role in maintaining homeostasis and repair in response to localized 
physiological and stress stimuli. 
 In the context of CNS insult, activated microglia are tightly regulated spatially and 
temporally in order to preserve an otherwise immunologically silent environment.  However, 
in many aspects, they resemble other macrophages and differentiated monocytes in 
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phenotype and function.  Upon activation, microglia acquire macrophage differentiation 
markers and effector properties, such as cytokine and chemokine receptors, scavenger 
receptor, death receptors/ligands (i.e. Fas/FasL), Fc receptors (i.e. Fcγ RI, RII, RIII), 
complement receptors (i.e. CR1, CR3, CR4, C1qRp), pattern recognition receptors (i.e. CR3, 
mannose receptor, CD14, or TLR4), and OX2R/CD200R (reviewed in [4, 12, 13]).  
Moreover, they release many effector and regulatory immune mediators.  In vitro and in vivo 
systems have demonstrated microglial production of proinflammatory cytokines, such as 
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-12, IL-15, and IL-18, and 
anti-inflammatory cytokines, such as IL-10, TGFβ, and IL-1 receptor antagonist (IL-1Ra).  
Matrix metalloproteinases (MMPs), chemokines, reactive oxygen species, inducible nitric 
oxide synthase (iNOS), and prostanoids have also been localized to activated microglia.  
Functionally, microglia are competent phagocytic cells that are able to clear myelin debris 
and apoptotic cells in a number of neurodegenerative diseases [13-20].   
 In addition to expressing the before-mentioned  receptors upon activation, microglia 
are able to alter their immunophenotype with upregulation of MHCI, MHCII, CD45, and 
adhesion/costimulatory molecules, such as LFA-1, LFA-3 (CD58), ICAM-1, CD40, B7-1 
(CD80), and B7-2 (CD86) (reviewed in [4, 12]).  Despite the activated immunophenotype, 
the capacity to present antigen by activated microglia is debatable.  Again, in the normal, 
physiological state of the parenchyma, MHC expression is minimal or absent, and when 
upregulated, it is restricted to a subset of microglia and astrocytes, the latter of which will be 
discussed in a later section [21-24].  Ample in vitro studies demonstrate that microglia from 
fetal or neonatal rodent or human brain are able to take up, process, and present antigen to 
naïve, memory, and differentiated T cells, leading to T cell proliferation and/or effector 
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functions (for examples, see [25-32]; reviewed in [4, 33]).  In contrast, several studies 
challenge the capacity of microglial antigen presentation [24, 34, 35].  Of these studies, a 
notable one by Ford and colleagues demonstrate the diminished ability of microglia purified 
from adult rat brain to present myelin basic protein (MBP) to CD4+ MBP-specific T cell line 
[24].  However, microglia were able to induce some T cell proliferation but they did not 
effectively stimulate IL-2 secretion when compared to macrophages. 
 Aside from microglia, there are several other blood-derived macrophages that 
circulate and reside in the CNS.  One type, in particular, is perivascular macrophages.  These 
cells are believed to have the greatest immunological importance in the brain.  Studies in 
early neonatal development demonstrate that perivascular microglia/macrophages leave the 
bone marrow and penetrate the BBB to colonize the CNS [6, 36, 37].  Perivascular 
microglia/macrophages are continuously replaced from the bone marrow, as they are usually 
found near small- and medium-sized blood vessels in or around the BBB [37].  They function 
in general maintenance of BBB integrity but are also key participants in immune surveillance 
[9, 38].  Unlike resident microglia, perivascular macrophages constitutively express MHCII 
[36, 39].  Because of their location, these cells rapidly sense immune-related alterations in 
the serum and are able to transduce proinflammatory signals from the periphery across the 
BBB and into the CNS parenchyma [9, 40].  Meningeal and choroid plexus macrophages are 
located tactically to guard the ventricular/subarachnoid compartment, have a high turnover 
rate, and have similar functions to perivascular macrophages [12, 41]. 
Microglia and macrophages in the CNS are a highly responsive population of cells.  
Their distribution throughout the parenchyma and sites of CNS entry makes them 
indispensable participants in immune surveillance and response.  Their role in 
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immunoregulation includes the following: expression of immune-related receptors, secretion 
of regulatory factors, antigen sampling and presentation, and effector functions, such as 
phagocytosis.  Their role in demyelination and remyelination, in regards to IL-1 and 
lymphocyte activation gene-3 (LAG-3, CD223), will be discussed in this dissertation. 
 
Astrocytes.  Astrocytes comprise a dynamic and, likely, heterogeneous cell population that is 
involved in physical structuring of the CNS, metabolism, synaptic functions, and response to 
infection, injury, or disease.  Physiologically, astrocytes aid in the maintenance of the 
extracellular ionic environment, uptake of extracellular glutamate that would otherwise 
negatively affect oligodendrocyte homeostasis, and aid neurons in development, function, 
and repair [42-44].  Additionally, these cells play an integral role, in conjunction with 
endothelial cells, in BBB formation and maintenance, limiting entry of leukocytes into the 
CNS.  In a forebrain stab injury study by Bush and colleagues, astrocytes were ablated by 
treating gfap promoter-driven HSV-thymidine kinase transgenic mice with gancyclovir [45].  
Injured tissue exhibited a prolonged 25-fold increase in leukocyte infiltration into the CNS 
and an inability to repair the BBB. 
In the context of CNS insult, the hallmark of astrocyte responsiveness is reactive 
gliosis, or astrogliosis, characterized by proliferation, hypertrophy of cellular processes, 
upregulation of glial fibrillary acidic protein (GFAP) and vimentin, and re-expression of 
nestin [44, 46, 47].  Activation is accompanied by expression of adhesion molecules [e.g. 
vascular cell adhesion molecule-1 (VCAM-1)], cytokines [e.g. IL-1, TNF-α, IL-6, 
lymphotoxin-α (LTα), granulocyte macrophage-colony stimulating factor (GM-CSF), TGFβ], 
chemokines [e.g. macrophage chemotactic protein-1 (MCP-1), fractalkine (CXC3CL1), 
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CXCL12 (SDF-1)], MMPs, and growth factors [e.g. fibroblast growth factor-2 (FGF-2), 
insulin-like growth factor (IGF-1)] (for examples, see [48-53] ; reviewed in [44, 54, 55]).  
Although not considered professional antigen presenting cells (APCs) that constitutively 
express MHCII and costimulatory molecules, reactive astrocytes have been shown to express 
MHCII, inducible by interferon-γ (IFNγ) in vitro [56].  However, their role in antigen 
presentation is unclear due to conflicting studies about their costimulatory molecules, namely 
B7-1 and B7-2 [43].  Furthermore, in vivo studies are not consistent in MHCII localization to 
astrocytes.  MHCII localization to astrocytes has not been demonstrated in mice 
constitutively expressing IFNγ in the CNS or in experimental autoimmune encephalomyelitis 
(EAE) rodents [43].  In contrast, MHCII has been localized to astrocytes during cuprizone-
demyelination; however, this is rather rare or occasional [23].   
Astrocytes can be classified as the “jack of all trades, master of none” in the CNS.  
These cells make up nearly half the brain parenchyma and appear to play supportive roles in 
maintaining CNS homeostasis, immune responsiveness to CNS insult and subsequent repair.  
In terms of demyelination, astrocytes have been shown to express LTα, which has been 
demonstrated to exacerbate demyelination but not affect remyelination [50].  LTα/β 
complexes can form between LTα and multiple subunits of LTβ and then induce signaling 
through LTβ receptor (LTβR), which is primarily expressed on microglia and also 
exacerbates demyelination [57].  Thus, LTα produced by astrocytes may exacerbate 
demyelination by associating with LTβ to form a LTα/β ligand that can then stimulate LTβR+ 
microglia. 
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Neurons.  Neurons are often overlooked as having significant immune contributions in 
response to CNS insult, mainly due to the lack of abundant MHCII expression inducible by 
IFNγ [58].  These cells, however, do play an important role in regulating glial cells, in 
particularly microglia in the physiological and diseased states (for an in-depth review, see 
[59]).  Recent studies have demonstrated constitutive expression of CD200 at the neuronal 
membrane surface.  These molecules are members of the immunoglobulin superfamily 
(IgSF) known to downregulate myeloid cell function [60, 61].  Moreover, in the CNS, 
microglia have been shown to express the receptor to CD200 (CD200R) [60, 62].  Wright 
and colleagues demonstrated that CD200R antibodies augment clinical signs of EAE, which 
was then accompanied by an increased macrophage influx [62].  Furthermore, these finding 
were corroborated by the same group in CD200-/- mice, which displayed aggravated 
symptoms and enhanced microglial activity during EAE [60].   
Other molecules expressed by neurons may have effects on microglia.  CD45 is 
expressed at low levels on microglia and is upregulated upon activation [4, 12].  This 
receptor has been shown to inhibit microglial activity [63].  CD22, the corresponding ligand, 
is released by neurons upon neuronal damage.  Moreover, it has been shown that MHCII 
induction in microglia can be restricted by neurotrophin release from electrically active 
neurons [64].  Of the downregulatory functions of neurons, a novel finding by Liu et al. has 
been pivotal in the re-examination of T-cell mediated multiple sclerosis by demonstrating 
that neurons are able to convert encephalitogenic T cells to regulatory T cells that dampen 
the immune response and inhibit EAE [65].  This phenomenon essentially turns their enemies 
into friends.  
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While neurons play this seemingly important role in downregulation of an active 
immune response in a typically immunologically silent environment, they can induce the 
opposite effect and upregulate microglia and other APCs when damage occurs.  Once 
injured, neurons release purines, such as ATP and UDP, which correspond to receptors, such 
as P2X4, P2Y12, and P2Y6, on microglia [59].  In vitro and in vivo studies demonstrate 
dynamic changes in microglial motility via P2X4 and P2Y12 receptor interactions with ATP 
[66].  Moreover, P2Y6 receptor activated by UDP stimulates the phagocytic effector function 
of microglia [67].  Thus, neurons may stimulate an immune response when the CNS is under 
duress. 
 Neurons are also involved in the critical relationship with oligodendrocytes at the 
axo-glial junctions ([68]; reviewed in [69]).  Several molecules and factors such as 
neuregulins, neurotrophins, contactin and neutrophil chemotactic protein-1 (NCP-1) on axons 
communicate with neurofascin 155 (NF155) on oligodendrocytes to promote myelination and 
formation of paranodes and Nodes of Ranvier.  The proper formation of the axo-glial 
structures is important for the saltatory conduction and function of nerves.  When there are 
perturbations to either the neurons or oligodendrocytes, degradation of the myelin ensues, 
leading to the degeneration of axons.  This appears to be significant in cuprizone-induced 
demyelination and multiple sclerosis, as axonal fallout occurs during episodes of 
demyelination [70].  This perturbation to myelin and axons results in responses by microglia 
that may be detrimental or reparative.   
Neurons play a significant role in the strict regulation of immune responses in the 
brain.  They serve to protect local microenvironments of brain tissue with intact neurons, in 
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spite of upregulation of neuroinflammation in nearby areas.  However, upon damage, they 
are capable of calling in professional APCs to clear infection and/or repair injury. 
 
Oligodendrocytes.  Oligodendrocytes are responsible for myelin sheath formation by 
extending and wrapping membrane processes around axons of many neurons in the CNS.  
Unlike Schwann cells, their counterparts in the PNS, oligodendrocytes are able to myelinate 
multiple axons.  Myelin is a phospholipid layer that electrically insulates axons and allows 
efficient transduction of nerve impulses along the axon.  Nodes of Ranvier are the gaps 
between the myelin sheets on which action potentials travel from one location along an axon 
to the next.  White matter tracts, such as the corpus callosum, are comprised of myelinated 
axon bundles.  Astrocytes and microglia are present within the white matter, as well as a 
small population of oligodendrocyte precursor cells (OPCs) [71].   
 OPCs are an endogenous pool of cells in the CNS capable of maturing into 
myelinating oligodendrocytes (reviewed in [72]).  They are present in high numbers 
throughout the embryonic brain, with a denser population in the ventral forebrain [73].  OPCs 
proliferate in germinal zones during embryogenesis and continue to proliferate as they 
migrate to their terminal destination, where they begin to differentiate and express myelin 
genes [74, 75].  In adult brain, OPCs are largely found in the subventricular zone (SVZ) and 
are distributed elsewhere in the CNS in low numbers [72]. Several factors have been 
demonstrated to promote proliferation and differentiation of OPCs, such as platelet-derived 
growth factor (PDGF), FGF2, and IGF-1 [76].  OPCs, as demonstrated in this dissertation 
and several publications, are recruited to demyelinating lesions and are responsible for 
remyelination. 
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 Oligodendrocyte differentiation has been well-studied using stage-specific antibodies 
in dissociated cell cultures, tissue sections, and in vivo.  Common markers that characterize 
their pattern of differentiation include the following: A2B5 and LB1 for early OPCs that 
proliferate in germinal centers during embryogenesis [77, 78], NG2 and PDGFRα for later 
OPCs that proliferate and migrate to areas for terminal differentiation [79], O4 for pro-
oligodendrocytes and immature oligodendrocytes [78, 80], and galactocerebroside [78], O1 
[80], and GSTpi [81] for mature oligodendrocytes.  Moreover, mature oligodendrocytes are 
often immunolabeled for myelin proteins, such as PLP, MBP, MOG, and MAG [82].  It 
should be noted that PLP has been demonstrated to be expressed by OPCs that are NG2+ 
[79].     
 
T cells.  T cells have been characterized to play a transient, immunosurveillence role in CNS 
immunity, passing through the brain parenchyma in search of their specific antigen.  Most 
studies indicate T cells may cross the BBB only in an activated state without regards to their 
antigen specificity [9].  However, it has been demonstrated that naïve cells can cross the 
BBB [83].  Interestingly, the number of T cells that traffic the CNS are in relatively low 
concentrations compared to other organs in the body, likely due to selectivity of the BBB 
[84, 85].  Once across the BBB, activated T cells are met with the anti-inflammatory 
environment of the CNS, partly due to constitutive expression of TGFβ.  Studies demonstrate 
that TGFβ suppresses T cell proliferation and the chemoattractants that permit leukocyte 
migration across the BBB (reviewed in [3]).  Moreover, T cells are also met by a hostile 
environment in which cell death via apoptosis is inherent.  Studies by Bauer et al. 
demonstrate that, in various models of autoimmune encephalitis, T cells in the CNS 
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parenchyma undergo apoptosis, a phenomenon that appears to be antigen recognition-
independent [86].  Similarly studies by Moalem et al. demonstrate extensive T cell apoptosis 
after CNS nerve injury that is not apparent after PNS nerve injury [1].  Both studies may be a 
result of Fas/FasL mechanisms.  Microglia, astrocytes, and neurons are capable of expressing 
FasL, and in the latter study, Fas was significantly upregulated in the CNS compared to the 
PNS [1, 87].  Despite this unfavorable environment, T cells readily cross the BBB and are 
able to engage in normal immune functions in the context of disease [9].  However, in T cell-
dependent demyelinating disease of the CNS, both autoimmune T cells and viral-specific T 
cells have been extensively studied and amply reviewed elsewhere [88-91].  In this 
dissertation, the cuprizone intoxication model will be used.  The BBB remains intact in 
C57BL/6 mice during demyelination, and there is no role for T cells in demyelination or 
remyelination [49, 92, 93]. 
                 
Neuroinflammation in CNS Repair.  The principal goal of any immune response is to protect 
the tissue from pathogens and/or to repair damaged tissue.  However, when the immune 
response is directed against self, insufficient, or prolonged, the repercussions can be 
devastating.  Recent studies have exploited the protective activities of the CNS in an 
inadequate or overactive immune response in order to promote repair and remyelination.  
Using the acute model of demyelination through administration of ethidium bromide, a 
recent study enhanced the innate immune response by a single intracerebral 
lipopolysaccharide (LPS) bolus and demonstrated increased accumulation of Olig1+ and 
Olig2+ OPCs, a cell type that later matures into myelin-producing cells [94].  Furthermore, 
the same study demonstrates dexamethasone, an anti-inflammatory agent, enlarged the size 
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of a lesion caused by Tween-20, a surfactant that provokes localized damage to cerebral 
tissue, thus demonstrating a protective role of innate immunity in acute brain injury.   
Inflammatory cytokines conventionally believed to contribute to oligodendrocyte 
death and myelin destruction may also contribute to CNS repair by recruitment and 
differentiation of oligodendrocyte progenitors.  TNF-α has been demonstrated to be 
neuroprotective by signaling through TNF receptor 2 (TNFR2) to upregulate the Akt-
1/protein kinase B (PKB)-dependent pathway [95].  Akt-1 stabilizes the mitochondrial 
membrane potential and prevents the release of cytochrome c and subsequent apoptosis [96].  
Another study suggests TNF-α-N-methyl-D-aspartate (NMDA)-dependent NFκB activation 
through TNFR2 protects neurons from glutamate neurotoxicity [97].  Furthermore, Arnett 
and colleagues demonstrated TNF-α/TNFR2 may be instrumental in oligodendrocyte 
proliferation and remyelination [49].  
 Growth factors and other neurotrophins are upregulated during CNS insult and have 
been shown to promote CNS repair and remyelination.  IGF-1 is a growth factor that directly 
affect oligodendrocytes and myelination and is required for normal oligodendrocyte 
development and myelination in vivo [98].  Moreover, IGF-1 has been shown to protect 
oligodendrocytes from TNF-α-induced death in vitro, and constitutive IGF-1 expression in 
mice (IGF-1Tg/o) has been demonstrated to protect mature oligodendrocytes from depletion 
during cuprizone treatment, resulting in rapid recovery from the demyelinating insult.  When 
IGF-1Tg/o are crossed with mice expressing the TNF-α transgene, there are twice the number 
of oligodendrocytes [99, 100].  As for other neurotrophins upregulated during CNS insult, 
organotypic slice cultures of adjacently placed brain cortex and spinal cord from neonatal 
rats with transplanted neural progenitor cells demonstrated that axon growth from the brain 
13 
 
cortex into the spinal cord was promoted by brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3) and nerve growth factor (NGF) released by the neural progenitor cells 
[101]. 
The subtle balance between neuroinflammation and neuroregeneration warrants 
careful elucidation of mechanisms discussed in this section in order to determine appropriate 
therapeutic approaches.   
 
1.2 Interleukin-1: The Prototypical Cytokine 
 
IL-1 is one of the most widely studied pro-inflammatory cytokines in the CNS.  There is 
extensive evidence implicating IL-1 as a key contributor to a diverse range of biological 
activities associated with infection, inflammation, and autoimmune processes, particularly in 
acute and chronic neurological disorders.  The canonical interleukin family is comprised of 
three proteins closely related in ancestry and structure: two functional agonists, IL-1α and IL-
1β, and one antagonist, IL-1 receptor antagonist (IL-1Ra) (reviewed in [102]).  Despite being 
encoded by different genes, IL-1α and IL-1β share high sequence homology and similar 
intron-exon organization.  Furthermore, both isoforms are synthesized as 31 kDa pro-forms 
lacking leader sequences and are cleaved to produce 17 kDa mature forms.  Despite similar 
biological effects of IL-1α and IL-1β, the two agonists differ in the cellular compartments in 
which they are primarily active.   
IL-1α is biologically active in its pro-form and can be cleaved by membrane-associated 
cysteine protease calpains to the active form.  Both forms largely remain intracellular, and 
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the mature form is only efficiently released by activated macrophages.  Other cell types 
express IL-1α; however, IL-1α is not released unless substantial cell injury occurs, such as 
ischemic brain damage [103].  In contrast, IL-1β is not biologically active in its pro-form and 
is cleaved by caspase-1 (IL-1β-converting enzyme, ICE) to form its mature counterpart 
[104].  IL-1β is mostly secreted by macrophages but can be secreted by other cells, such as T 
cells.  Keller et al. recently described that activation of caspase-1 by inflammasome 
complexes is directly linked to a non-classical secretion pathway by which both agonists, 
despite IL-1α not being processed by caspase-1 and in addition to other leaderless proteins, 
are secreted [105].  IL-1α and IL-1β are believed to induce similar cellular responses, as they 
both bind a common receptor, IL-1 type 1 receptor (IL-1R1), which recruits the IL-1 receptor 
accessory protein (IL-1RAcP) and activates intracellular signaling pathways including 
nuclear factor κ B (NFκB) and mitogen-activated protein kinases (MAPKs) [106, 107].  IL-
1R1 signals through the Toll/IL-1 receptor (TIR) domain, a conserved intracellular region, 
which recruits adaptors, such as myeloid differentiation factor 88 (MyD88) and TNF 
receptor-associated factor 6 (TRAF6) [108].  Signaling may lead to the induction of other 
immunomodulators, such as IL-6, TNF-α, and prostaglandin E2 (PGE2).  Additionally, IL-1α 
and IL-1β are able to bind a second receptor, IL-1R2, which lacks an intracellular domain.  
Acting as a decoy receptor, downstream signaling through IL-1R2 does not occur.  
Interestingly, a study using mixed glial cultures from IL-1R1-/- mice demonstrates an 
upregulation of several genes that are independent of the classical NFκB and MAPK 
pathway, suggesting against IL-1R1 as the sole functional receptor for IL-1 [109].   
IL-1Ra is unique in being an endogenous competitive antagonist in a cytokine signaling 
system.  It is synthesized in three intracellular forms and one secreted form by the same cells 
15 
 
that produce IL-1.  While the roles of the intracellular forms of IL-1Ra remain poorly 
defined, the secreted form binds IL-1R1 to competitively inhibit binding of the agonists and, 
thus, effectively block IL-1 signaling.   
In addition to IL-18, several new IL-1 family members have been identified based on 
gene homology (sequence similarity of 20-52% with IL-1α, IL-1β, and IL-1Ra), gene 
location, and receptor binding: IL-1F5 (IL-1 family, member 5), IL-1F6, IL-1F7, IL-1F8, IL-
1F9, and IL-1F10 (reviewed in [110-113]).  In relevance to this dissertation, key family 
members and their role in neurological disorders will be discussed.     
 
Regulation of IL-1 production and activity.  IL-1 is expressed at low constitutive levels in the 
healthy CNS [114].  Regulation of IL-1 is tightly regulated and is multi-tiered: transcription, 
translation, cleavage, cellular release, and bioactivity.  However, IL-1 appears to be 
dispensable for the CNS development, as the brains of IL-1-/- mice appear normal [115, 116]. 
The expression of IL-1α and IL-1β may differ in correlation to their promoter 
elements.  The promoter for the IL-1α gene does not contain sequences that correspond to the 
TATA box, a typical motif for inducible genes [102].  Inducible gene expression is controlled 
by a 4.2 kb upstream region and a proximal promoter region of 200 bp [102].  Seemingly, 
downstream sequences can be deleted without consequence to gene expression.  In contrast, 
the IL-1β gene possesses a TATA box in its promoter region, as well as a CAAT box, which 
controls the efficiency of transcription initiation [117].  IL-1β gene transcription is complexly 
controlled.  Unlike most cytokine promoters, the regulatory regions of IL-1β are distributed 
over several thousand basepairs downstream from the transcriptional start site [102].  
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Notably, there are two enhancer regions that act cooperatively: one that contains a cyclic 
AMP (cAMP) response element and a NFκB-like site and another that is a composite cAMP 
response element-NF-IL6 and is responsive to LPS [102, 118].  Activating protein-1 (AP-1) 
also participates in LPS-induced IL-1β expression.  Moreover, there are several binding 
regions for transcription factors, such as nuclear factor-βA (NFβA) and SP1, which impart 
tissue specificity.  Undeniably, IL-1β gene regulation is under sophisticated transcriptional 
control and is selectively triggered by a number of immune insults, such as LPS or, more 
relevant to the CNS, β-amyloid. 
 IL-1β protein production is regulated in several ways.  Characteristic of IL-1β, and 
also to TNF-α, there appears to be a disconnection between transcription and translation 
[119].  For example, during hypoxia, pro-IL-1β mRNA transcripts are synthesized in large 
amounts in monocytes; however, this is not always accompanied with translation into the 
pro-IL-1β protein.  In this case, the signal for translation may not be sufficient.  
Contrastingly, LPS has been shown to increase IL-1β protein synthesis by stabilization of the 
transcript.  However, cellular release of IL-1β requires additional signals [120].  In the case 
of LPS-primed macrophages, subsequent activation of P2X7 by ATP is required for cleavage 
of pro-IL-1β by caspase-1 and release, which is dependent on marked changes in ionic 
composition [121].  Stimuli other than ATP may serve as the signal that induces cleavage and 
subsequent release but common to these stimuli is the capability of stimulating ionic flux.  A 
small antimicrobial peptide LL37 (CAMP), released by neutrophils and epithelial cells, has 
been identified to induce P2X7 activation and subsequent IL-1β release [122].  As with most 
processes, there are counter-pathways.  IL-1β release has been demonstrated to be blocked by 
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a family of cytokine-release inhibitory drugs (CRIDs) (for characterization, see [123]).  This 
family does not appear to function through P2X7. 
 Lastly, IL-1β activity is regulated upon cellular release by several mechanisms 
including competitive binding for receptors and expression of the receptors [124].  As 
mentioned previously, IL-1Ra serves as an endogenous competitor for IL-R1.  However, it 
has been demonstrated that IL-1Ra concentrations need to be in 100-fold excess relative to 
IL-1 in order to block IL-1 signaling.  Thus, during inflammation, upregulation of IL-1Ra 
may not be adequate in countering IL-1-mediated activities.  Additionally, IL-1R1, IL-1R2, 
and IL-1RAcP can be shed from the membrane.  IL-1R1 and IL-1R2 function in the 
sequestering of the IL-1 agonists, and IL-1RAcP sequesters IL-1R1.  Furthermore, IL-1R2 
can bind IL-1RAcP, preventing recruitment to IL-1R1.  Again, IL-1, a potent 
immunoregulator, needs only a few receptors to induce immune-related biological activities.  
Thus, these regulatory mechanisms may be more functional in maintaining physiological 
homeostasis rather than taming IL-1 mediated activities during inflammation.  The extent to 
which IL-1 is mitigated demonstrates the potential biological importance of IL-1. 
 
IL-1 in the CNS.  All members of the canonical IL-1 family, namely IL-1α, IL-1β, IL-1Ra, 
IL-1R1, IL-1R2, and IL-1RAcP, are expressed in the CNS [114].  However, the cellular 
source of IL-1 remains elusive, as expression is very low to undetectable in normal brains 
and many studies for the cellular expression of IL-1 are performed in vitro and in the context 
of CNS injury.  During injury or disease, however, microglia and astrocytes have been shown 
to express IL-1 and this is discussed in greater detail below.  Furthermore, the function of 
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these IL-1 family members, even the well-characterized IL-1β, in the normal CNS also 
remains somewhat elusive.  Genetic knockout mice lacking IL-1α and/or IL-1β, as well as 
IL-1RI, develop normally with no obvious differences from wild type mice.  However, in 
Chapter 2 of this dissertation, we characterize a novel finding in mature oligodendrocyte 
populations in mice lacking IL-1β.   
One of the few known physiologically important roles for IL-1 is its function in sleep 
patterns.  A study in 1991 administered IL-1Ra to rabbits and observed reduced non-rapid 
eye movement sleep [125].  It also has been reported that IL-1RI-/- mice sleep less than wild 
type control mice [126].  Moreover, IL-1 concentrations are higher in the brain during sleep 
[114].  A second role of IL-1 has been associated with synaptic plasticity.  Increased IL-1 
expression has been observed after induction of long-term potentiation (LTP) in the 
hippocampus [127].  Moreover, IL-Ra impairs the maintenance phase of LTP [127].  Thus, 
IL-1 appears to affect subtleties in neuronal function; however, there are no reports yet of 
other roles for IL-1 in the physiologically normal CNS. 
Microglia are the early primary source of IL-1 following CNS injury, infection, or 
inflammation, which is not surprising considering that monocytes and macrophages are the 
primary source in the periphery [128].  Astrocytes also express IL-1 and usually follow 
microglia in expression after CNS insult.  Furthermore, oligodendrocytes, neurons, and 
cerebrovascular cells have been reported to express IL-1 [129].  IL-Ra and the IL-1 receptors 
are usually induced by the same stimuli that upregulated IL-1 and, thus, are expressed on the 
same cell types [129-133].   In cuprizone-induced demyelination, nearly all microglia and 
about 50% of astrocytes express IL-1 [51].  Of interest to this dissertation is how IL-1 affects 
astrocytes, oligodendrocytes and neurons rather than which cells express IL-1. 
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Microglia express IL-1R1 to which IL-1 can directly bind and induce expression of 
several immune mediators: reactive oxygen species, reactive nitrogen species, PGE2, 
proinflammatory cytokines, and chemokines (see Section 1.1: Microglia/macrophages; 
reviewed in [134]).  Rat microglia also can be stimulated to produce several anti-
inflammatory cytokines: such as IL-10, TGFβ, and IL-1Ra.  There is, however, a species-
specific difference in IL-1 signaling, as mouse microglia express low levels of IL-1R1 and, 
thus, fail to induce signaling in vitro [133].  Effectively, they behave similarly to peripheral 
macrophages. 
Of the CNS cell types, astrocytes appears to be most affected by IL-1 (reviewed in 
[135]).  In addition to stimulating proliferation, or rather astrogliosis, IL-1 signaling in 
astrocytes plays a key role in leukocyte migration [135, 136].  As previously mentioned, 
astrocytes are an integral part of regulating cell entry through the BBB.  Studies demonstrate 
that IL-1 induces sustained expression of the chemoattractant cytokine IL-8 and adhesion 
molecules, VCAM-1 and ICAM-1, in astrocytes [137, 138].  Interestingly, this may play a 
key role in MS and Alzheimer’s disease, where expression of leukocyte adhesion molecules 
in astrocytes and leukocyte entry is high [139, 140].  Additionally, like microglia, IL-1 
signaling can induce production of pro- and anti-inflammatory immune mediators.  
Microarray analysis reports that IL-1 upregulates neurotoxic mediators, such as chemokines, 
MMPs, proinflammatory cytokines (IL-6, TNF-α), and survival mediators, such as NGF 
[141].   
Despite expression of IL-1 and its functional receptor, oligodendrocytes, the cell type 
responsible for myelin sheath formation, have been poorly studied in terms of IL-1 effects.  
Interestingly, Vela and colleagues demonstrated that IL-1 inhibits proliferation and promotes 
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differentiation of OPCs, as well as promoting maturation and survival of differentiating 
oligodendrocytes in vitro [142].  This study could translate to profound effects in vivo, 
suggesting IL-1 may promote remyelination.  In line with this notion, IL-1β has been shown 
to be important for remyelination in cuprizone-induced demyelination and for stimulation of 
oligodendrocytes in response to Fcμ that promotes CNS repair [51, 143].  In contrast, IL-1Ra 
over-expression has been shown to ameliorate EAE, suggesting that IL-1 is detrimental 
[144]. Thus, IL-1 can affect astrocytes and oligodendrocytes in harmful or beneficial ways.   
 
IL-1 in CNS Disease.  IL-1 expression is increased in several neurological disorders with 
varied etiology and presentation: multiple sclerosis, amylotrophic lateral sclerosis, 
Alzheimer’s disease, Parkinson’s disease, prion diseases, HIV-associated dementia, and 
epilepsy.  However, it is unknown whether IL-1 is a contributing factor to disease or rather it 
is part of the immune response that triggers resolution of inflammation and initiates 
reparative processes.  Several studies of IL-1 in CNS disease are discussed below. 
 IL-1β is indirectly implicated in ALS, a motor neuron degenerative disorder in which 
25-30% cases are associated with mutations in the superoxide dismutase gene (SOD1) [145].  
A study by Pasinelli and colleagues demonstrates that mutant SOD1 promotes apoptosis in 
an oxidatively stressed neuroblastoma cell line by activating caspase-1, which subsequently 
cleaves pro-IL-1β and promotes release of the mature form [145].  Furthermore, activation of 
caspase-1 and subsequent cleavage of pro-IL-1β was confirmed in two transgenic strains of 
mice expressing mutant SOD1 proteins.  Interestingly, an independent study demonstrates 
inhibition of caspase-1 retards clinical symptoms of ALS-like symptoms in mutant SOD-1 
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transgenic mice [146].   This study suggests that IL-1 may exacerbate ALS-like symptoms 
and inhibition of IL-1 may be an effective therapeutic strategy to explore further. 
More recently, human post mortem spinal cord specimens from MS and ALS patients 
were examined for cyclooxygenase-2 (COX-2) and P2X7 expression in activated 
microglia/macrophages [147].  There is significantly more COX-2+ microglia/macrophages 
in MS spinal cord compared to controls, while P2X7+ microglia/macrophages were more 
populous in both MS and ALS spinal cords.  This study suggests that activation of P2X7-
induced IL-1β secretion stimulates COX-2 and downstream pathogenic mediators, thus 
giving value to P2X7 and COX-2 inhibitors as possible therapeutic agents in MS and ALS.  
It should be noted that COX-2 inhibition prolongs survival in animal models of ALS and 
thus, IL-1 appears to be detrimental to these diseases.   
Prion diseases are fatal neurodegenerative disorders that are caused by the 
conformational change of a ubiquitously-expressed and noninfectious prion protein (PrPC) to 
a disease-associated isoform (PrPSc) [148].  Previous experiments demonstrate that any gene 
product involved in PrPSc formation affects the onset of prion disease if knocked out or 
overexpressed [148].  Interestingly, Tamguney et al. demonstrated prolonged onset of disease 
in IL-1R1-/- mice.  Thus, this study implicates a possible role of IL-1R1, and thus IL-1, in the 
conformational change of PrPC to its disease-associated isoform. 
 
IL-18.  IL-18 should be noted because of its emergence as a prominent cytokine in 
neuroinflammation and neurodegeneration.  IL-18, originally identified as IFNγ-inducing 
factor, is similar to IL-β in several ways [reviewed in [149, 150]].  It is synthesized in a 24 
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kDa, biologically inactive pro-form that lacks a signal sequence.  Cleavage by caspase-1 
forms the 18 kDa, biologically active counterpart.  IL-18 binds IL-18 receptor (IL-18R; IL-1-
receptor-related protein), which recruits IL-18 receptor accessory protein (IL-18AcP) to 
initiate signal transduction.  Like IL-1/IL-1R1 signaling, IL-18/IL-18R signaling leads to 
NFκB activation and subsequent expression of pro-inflammatory cytokines, such as IL-1β 
and TNF-α, chemokines, iNOS, and cell adhesion molecules [151].  Additionally, IL-18 is 
able to induce FasL.  Unlike IL-1, IL-18 able to induce IFNγ but is unable to induce COX-2, 
which results in upregulation of PGE2.  Interestingly, IL-18 also has an endogenous 
antagonist, IL-18 binding protein.  However, it functions not by binding IL-18R but, instead, 
binds and sequesters IL-18.  IL-18BP has a high affinity only for the mature form.   
 Microglia, astrocytes, neurons, and ependymal cells constitutively express IL-18, IL-
18R, and caspase-1 [149]. IL-18BP has been demonstrated to be constitutively expressed on 
primary microglia in vitro and in normal rat brain in vivo.  Interestingly, IL-18 expression in 
the brain is higher in postnatal stages and is downregulated to low, almost undetectable levels 
in the adult, suggesting a role in brain development. Unfortunately, few studies have 
examined IL-18 in development.  IL-18-/- mice develop with no observable abnormalities 
[152].   
 IL-18 and caspase-1 have been implicated in playing a role in neurodegeneration, 
particularly in MS and EAE.  In the periphery, IL-18 has been demonstrated to induce Th1 
and Th2 helper T cell responses [153].  Clinical symptoms of EAE were mitigated upon 
administration of caspase-1 inhibitors, as well as in caspase-1-/- mice.  This has been 
attributed to the capability of the IL-18/caspase-1 pathway to modulate Th1 responses.  
However, the IL-1/caspase-1 pathway cannot be dismissed.  In support of the former 
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hypothesis, clinical symptoms of EAE were exacerbated in wild type mice administered 
exogenous IL-18 [154].  Furthermore, IL-18-/- mice appeared resistant to EAE. 
 
1.3 LAG-3: A Two-Way Signaling Molecule 
 
 LAG-3 is a membrane-bound glycoprotein that shares many structural similarities to 
CD4.  It is expressed in all subsets of T cells and a subset of natural killer (NK) cells 
following cellular activation [155-157].  Recently it has also been identified on B cells [158].  
Deemed as a “two-way signaling” molecule, LAG-3 is expressed on activated T cells and 
binds MHCII, its only known ligand [156, 159], on APCs and induces two cellular functions: 
(1) downregulation of T cell receptor (TCR) signaling, leading to cell inactivation and [160, 
161]; (2) activation of monocytes and dendritic cells, leading to optimal MHCI and MHCII T 
cell responses [162-164].  Although LAG-3 mRNA expression has been demonstrated in 
brain tissue, there is a lack of literature addressing the CNS cell type that expresses LAG3 
and the role it may play in the physiological and diseased states [157].  However, there is no 
reason to assume that the same processes LAG-3 carries out in the peripheral immune cells 
cannot be applied to the CNS, particularly because the relevant regulatory molecules are 
expressed there. 
 
Structure.  Human LAG-3 was first characterized in 1990 by Triebel and colleagues who 
focused on genomic organization and structure [155].  The LAG-3 gene includes eight exons 
and encodes a 498-amino acid membrane protein with four extracellular IgSF domains.  The 
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first domain (D1) belongs to the V-SET, which is an Ig-like domain resembling the antibody 
variable domain.  Interestingly, D1 contains a proline-rich 30 amino acid loop in the middle 
of the domain and an unusual disulphide bridge (Figure 1.1).  As a side note, an unusual 
disulphide bond of a different kind has been reported in the V-like domain of the CD8α chain 
[165].  Mutagenesis studies show that the V-type Ig-like D1 domain includes the MHCII 
binding site on LAG-3 [159].  Additionally, a prospective second binding site is located on 
D1 and is believed to be involved in LAG-3 oligomerization.  Huard et al. postulates that 
LAG-3 oligomerization induces structural changes in the MHCII binding site than enhances 
complementation at the interface between LAG-3 and MHCII [159].  Supportive of this 
hypothesis, LAG-3 has a 100-fold stronger binding affinity to MHCII compared to soluble 
CD4, which has a binding affinity < 104 [159, 166-168].  Also, LAG-3 binds MHCII on a site 
that is distinctive from CD4, as MHCII antibodies that are able to block CD4 interaction are 
unable to block LAG-3 [166].  D2, D3, and D4 belong to the C2-SET, which is a protein 
structural domain that aids in targeting proteins to the cell membrane [155].  Despite <20% 
amino acid sequence identity with CD4, LAG-3 is strikingly similar in structure to CD4: both 
genes contain an intron within the first IgSF domain and the positions of their introns are 
almost analogous.  Both genes are located on the distal part of the short arm of chromosome 
12 and, because both genes have internal sequence homologies between D1 and D3 and 
between D2 and D4, have been proposed to share a common evolutionary ancestor.   
 Of note, in cloning of murine LAG-3, Mastrangeli and colleagues describe interesting 
motifs in the cytoplasmic domain, which is distinctly different from CD4 [169].  There are 
three conserved regions between murine LAG-3 and human LAG-3: (1) a potential serine 
phosphorylation site, which may be analogous to the CD4 protein kinase C binding site, (2) a 
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conserved KIEELE motif with no homology to other proteins, (3) an unusual glutamic acid-
proline (EP) repetitive sequence.  The latest motif is postulated to mediate interactions with a 
broad range of molecules or ubiquitous proteins that perform a common function.  Signaling 
molecules, such as platelet-derived growth factor receptor (PDGFR), contain an EP domain, 
and thus the cytoplasmic tail is implicated in a potential role in intracellular signaling and 
molecular aggregation [170].  Interestingly, deletion of this cytoplasmic tail has been 
demonstrated to result in the loss of LAG-3 inhibitory effects on CD4+ T cell function [170]. 
 
Tissue Distribution.  Initial studies of LAG-3 expression were performed in healthy human 
tissues, which exhibited little to no LAG-3+ cells in peripheral blood mononuclear cells 
(PBMCs), primary lymphoid tissues, such as thymus and bone marrow, and secondary 
lymphoid tissues, such as spleen, mucosa-associated lymphoid tissue, and lymph nodes 
[171].  However, in hyperplasic lymph nodes, germinal centers and interfollicular areas 
consistent with T cell populations immunostained positively for LAG-3.  Moreover, cancer 
patients with high-dose IL-2 infusions had elevated numbers of LAG-3+ PBMCs.  It should 
be noted that only a fraction of the LAG-3+ cells were CD25+, a marker on activated T and B 
cells. 
 The distribution of murine LAG-3 expression by Western blot exhibits strong signal 
in the thymus, spleen, and areas of the brain outside of the cerebellum [157].  Interestingly, in 
situ hybridization revealed LAG-3 gene expression is restricted to sparse cells throughout the 
cortex and confirmed the absence of LAG-3 in the cerebellum.  In contrast, day 7 postnatal 
brain exhibited LAG-3 gene expression in defined tracts at the base of the cerebellum, in the 
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developing white matter, and in the choroid plexus.  A similar study in the rat revealed a 
slightly expanded distribution with LAG-3 message also appearing in the lung, liver and 
small intestine, and again, there was also strong message in the brain tissue [172].  In rodent 
tissue, the expression pattern of LAG-3 mRNA largely correlates with tissues that contain 
active T cell and NK cell tissue, with the exception of the brain. 
 
LAG-3: A Negative Regulator of T Cells.  The initial observation that LAG-3 had an 
inhibitory effect was suggested by the upregulation of CD4+ T cell clone activation.  Soluble 
anti-LAG-3 antibodies that effectively blocked MHCII interaction increased thymidine 
incorporation in CD4+ T cells, as well as enhanced CD25+ expression and production of IFNγ 
or IL-4 [160].  This study was followed up by Hannier and colleagues, who demonstrated 
that binding of LAG-3 antibody to LAG-3 followed by crosslinking (LAG-3XL) led to 
inhibition of cell proliferation and cytokine secretion by pre-activated T cells [161].  
Importantly, the physical interaction of LAG-3 and TCR/CD3 was demonstrated by LAG-3-
XL down-modulation of CD3/TCR, inhibition of calcium response to CD3 stimulation upon 
LAG-3 and CD3 co-engagement, and capping of CD3 resulted in co-capping of LAG-3 
molecules.  Ultimately, this study demonstrated the inhibitory effects of LAG-3 signal on 
TCR-induced activation.   
It has been postulated that “supramolecular assemblies” between LAG-3, CD3, CD8, 
and MHCII may result from the organization within lipid raft microdomains [173, 174].  
These microdomains provide clustering sites for signaling molecules and are required for 
efficient T cell activation.  Clustering of rafts brings the TCR and MHC molecules within the 
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vicinity of each other, forming an immunological synapse, for the purpose of TCR antigen 
recognition.  Hannier and colleagues demonstrated that engagement of CD3/TCR complexes 
with anti-TCR-specific antibodies or MHC-peptide complex recognition in T cell-B cell 
conjugates results in LAG-3 being co-clustered with the CD3/TCR complexes [174].  
Moreover, following CD8 or MHCII engagement, LAG-3 also was found co-clustered with 
the respective molecules.  A follow-up study by the same group found LAG-3 and MHCII in 
the cell fractions of these detergent-insoluble lipid rafts after centrifugation of Triton X-100-
treated activated T cells on sucrose gradients [173].  These studies propose a means by which 
LAG-3 can physically engage respective immune molecules.  The most telling experiments 
of the negative regulatory capacity of LAG-3 are done in the LAG-3-/- mouse.  In 2004, 
Workman et al. demonstrated (1) LAG-3-/- T cells exhibited a delay in cell cycle arrest upon 
in vivo stimulation with staphylococcal enterotoxin B, thus leading to increased T cell 
expansion and splenomegaly, (2) increased T cell expansion in adoptive recipients of LAG-3-
/- OT-II TCR transgenic T cells following antigen stimulation in vivo, (3) Sendai-viral 
infection in LAG-3-/- mice increased memory CD4+ and CD8+ T cells, and (4) LAG-3-/- mice 
infected with murine gammaherpesvirus-68 exhibited a delayed CD4* T cell expansion [175].  
Ultimately, these studies confirmed the role of LAG-3 in regulating expansion of activated T 
cells and the development of the memory T cell pool.   
Recent studies have focused on LAG-3 and regulatory T cells (Tregs), a cell type that 
functions in the inhibition of effector T cells and in maintenance of immune homeostasis.  A 
pivotal study in 2004 revealed that LAG-3 is selectively upregulated on Tregs [176].  
Moreover, this study demonstrates that LAG-3 inhibits the suppressive functions of Tregs in 
vitro and in vivo and that ectopic expression of LAG-3 on CD4+ T cells is sufficient for 
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reducing proliferation.  Interestingly, studies in LAG-3-/- demonstrate that LAG-3 regulates T 
cell homeostasis by Treg-dependent and independent mechanisms [177].  In the absence of 
LAG-3, Tregs were unable to sufficiently maintain optimal control of T cell homeostasis in 
vivo.  Furthermore, dysregulation of T cell homeostasis led to expansion of multiple cell 
types, such as B cells, macrophages, granulocytes, and dendritic cells. 
The evidence of negative regulatory function of LAG-3 on T cells is ever-expanding 
[178].  Interestingly, despite LAG-3 expression in the brain, very few T cells are present in 
the physiological state.  It can be inferred that LAG-3 may be expressed on a different cell 
type in the CNS, as will be addressed in Chapter 3. 
  
LAG-3: An APC Activator.  MHCII signal transduction has been demonstrated on several cell 
types including B cells, T cells, and monocytes using primarily antibodies to MHCII.  
Although the interaction of MHCII signal transduction is presumed to be engagement of 
TCR, recent evidence indicates that LAG-3 may also activate monocytes and dendritic cells 
[164].  LAG-3 in conjunction with CD40L was shown to activate TNF-α and IL-12 secretion 
from dendritic cells.  Blocking the LAG-3/MHCII engagement prevented signaling from 
MHCII+ cells and also inhibited T cell responsiveness to IL-12.  However, this study was 
conducted with human T cells stimulated with IL-2, and it is plausible that interaction could 
be different with Tregs interacting with dendritic cells to achieve immunosuppression [178]. 
 
LAG-3 in multiple sclerosis.  Due to the lack of research on LAG-3 in the CNS, there has 
been only one reported link to CNS disease.  In 2005, LAG-3 was flagged as a potential 
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susceptibility marker for MS [179].  However, since this initial study, LAG-3 association 
with risk of multiple sclerosis (MS) has become debatable.  The LAG-3 gene was studied in 
two independent sample sets of MS patients and healthy controls [179, 180].   Although the 
gene was reported initially to be associated with risk of multiple sclerosis (MS) [179], it 
failed to be replicated in an independent case-control study using a larger patient pool [180].  
It must be noted that the lack of genetic evidence for a role in determining risk of disease 
does not preclude the potential importance for LAG-3 in MS pathogenesis.   
 
1.4 The Cuprizone Intoxication Model of Demyelination and Remyelination 
 
Cuprizone (bis-cyclohexanone oxalyldihydrazone) was characterized in the late 1960s 
as a CNS demyelinating agent when fed in low doses to mice [181, 182].  This toxic insult 
resulted in spongy degeneration and oligodendrocyte cell death [182-184].  By the early 
1970s, Blakemore comprehensively characterized cuprizone-induced demyelination and 
remyelination after the removal of cuprizone from the diet [185, 186].  Importantly, 
Blakemore’s characterization established reproducibility in myelination patterns, as well as 
activation of glial cells and their recruitment during temporally-defined stages of cuprizone 
treatment.  The majority of these earlier studies in understanding of demyelination and 
remyelination relied heavily on morphology through electron micrographs, and there was 
only a limited immunohistochemical analyses.  With the availability of genetic knockout and 
transgenic mice, the cuprizone intoxication model has since been adapted to the C57BL/6 
background [187].  Moreover, our laboratory has re-characterized a lower dose of cuprizone 
treatment, compared to the dosing in previous strains of Swiss Webster, Swiss albino, or ICI 
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mice, that allows efficient and reproducible demyelination of the corpus callosum without 
systemic toxicity [187].  More importantly, a different pattern of demyelination and 
remyelination has been described for C57BL/6 mice that suggest strain variability with 
regards to disease presentation [188]. 
 
Mechanism of Action.  Cuprizone is a copper chelator and when bound to copper forms a 
highly chromogenic complex that possesses very intense and unusual absorption band in the 
visible region, centered at 595 nm [189].  Thus, it is often exploited in clinical chemistry for 
spectrophotometric determinations of copper [189].  However, in mice dosed with cuprizone, 
the mechanism by which cuprizone induces CNS demyelination is unknown.  Copper is an 
essential trace element and is a cofactor in many metalloenzymes [190].  Cuprizone exposure 
results in a copper deficiency in the brain, as well as a decrease in copper-dependent 
enzymes, such as monamine oxidase and cytochrome oxidase [191, 192].  Chelation of 
cuprizone prior to administration prevented these symptoms [191].  However, administration 
of dietary copper does not alleviate cuprizone-induced neurotoxic effects [182].   
 It is hypothesized that cuprizone may inhibit mitochondrial enzymes, such as 
monamine oxidase, resulting in metabolic perturbation and cell injury [191].  Interestingly, 
oligodendrocytes appear to be preferentially susceptible to cuprizone effects, as several 
oligodendrocyte-associated proteins are down regulated upon treatment before histological 
demyelination is evident: glutathione-S transferase (GSTpi), 2’3’-cyclic nucleotide 3’-
phosphohydrolase (CNPase), carbonic anhydrase II (CAII), and myelin proteins, such as 
myelin-associated glycoprotein (MAG) and myelin basic protein (MBP) [193-196].  Minor 
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irregularities have been observed in the mitochondria of oligodendrocytes [183, 197].  Thus, 
this preferential susceptibility to cuprizone may be a result of the inability of the 
oligodendrocyte to meet the high metabolic demand of maintaining the myelin sheath. 
Oligodendrocytes have been demonstrated to undergo apoptosis during cuprizone 
intoxication [198].  A recent study demonstrated in vivo inhibition of microglial activation 
with minocycline prevented cuprizone-induced demyelination in Swiss mice [199].  Based on 
in vitro experiments in primary rat oligodendroglial cultures, this group attributed 
oligodendrocyte protection to the absence of proinflammatory cytokines, such as TNF-α and 
IFNγ,  produced by the otherwise present microglia [199].  This suggests that microglial 
factors may contribute to the cuprizone insult to tip oligodendrocytes towards apoptosis.  
Regardless of the exact mechanism, cuprizone administration triggers oligodendrocyte cell 
loss with subsequent CNS demyelination. 
 
Historical perspective.  Initial characterization of cuprizone intoxication was reported in the 
late 1960s to cause widespread spongiosis and oligodendrocyte cell death in the brain, often 
accompanied by hepatic disturbance [181-184].  These observations were made in various 
mouse strains: Swiss-Webster, Swiss albino, and ICI.  Interestingly, this spongy degeneration 
in cuprizone-fed mice was similar to that in found in scrapie [200, 201].   
In 1973, Blakemore published the first comprehensive studies characterizing glial 
responses and myelination in the superior cerebellar penducle of ICI mice during 0.5% 
cuprizone-induced demyelination and remyelination after the removal of cuprizone from the 
diet [185, 186].  As early as 1 week of cuprizone treatment, pyknotic oligodendrocytes were 
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observed prior to the presence of demyelinated axons.  By 2 weeks of cuprizone treatment, 
myelin sheaths displayed signs of disintegration, partially attributed to microglial stripping of 
myelin lamellae and phagocytosis of vacuolated myelin [184].  Glial populations, namely 
microglia and astrocytes, accumulated dramatically during demyelination and were found in 
direct proximity to naked axons.  Upon removal of cuprizone administration, these glial 
populations diminished.  As mentioned previously, Blakemore’s characterization established 
reproducibility in myelination patterns, as well as activation of glial cells and their 
recruitment during temporally-defined stages of cuprizone treatment.  Moreover, he 
demonstrated remyelination could be studied in a model that was highly reproducible.   
 Swiss mice studies with 0.6% cuprizone administration displayed a similar temporal 
ability to demyelinate upon intoxication and remyelinate upon cuprizone removal [197].  In 
these studies, Ludwin observed myelin wrapping during remyelination was comparable to 
that in development.  Moreover, he suggests that the population of remyelinating 
oligodendrocytes are comprised of residual surviving oligodendrocytes, as well as newly 
proliferating and differentiating OPCs.  It should be re-noted that in C57BL/6 mice, Mason et 
al. demonstrated the apoptosis of oligodendrocytes, suggesting repopulation is from new 
population of proliferating and differentiating OPCs [198].   
 In addition to demyelination and remyelination, axonal integrity has been examined 
thoroughly in cuprizone-induced chronic demyelination.  Axons in Swiss mice subjected to 
cuprizone treatment for 6 to 7 months retained their capacity to remyelinate [202].  
Moreover, axonal diameter was only slightly decreased.  Since these studies, Mason et al. 
characterized chronic cuprizone treatment in C57BL/6 mice and found that the regenerative 
capacity of axons were exhausted by 16 weeks, when the mice were near death [188].  
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Moreover, this study demonstrated a significant reduction in axonal diameter during acute 
demyelination that returned to near-normal upon remyelination.  Furthermore, in mice 
chronically-treated for 16 weeks, axons were reduced to 60% of normal axonal diameter.  
Recent studies by Blakemore suggest aged mice (6-7 months), compared to young adult mice 
(7-8 week old), respond to cuprizone with greater incidence of axon transaction, greater 
axonal loss in the medial corpus callosum, and a more robust glial response [203].  
Retrospectively, these studies demonstrate a genetic- and age-susceptibility to axonal 
degeneration associated with demyelination. 
 There are several features of the cuprizone intoxication model that distinguish it from 
others models of demyelination, such as EAE, Mouse Hepatitis Virus (MHV) or Theiler’s 
murine encephalitis virus (TMEV).  The cuprizone model, despite various dose 
concentrations and mouse strains, displays temporally and spatially consistent demyelinated 
lesions throughout the brain, such as the superior cerebellar penducle and corpus callosum.  
The lack of anatomical reproducibility in EAE or viral models hampers the ability to make 
reliable assessments of changes in cellular populations, myelination quantifications, and 
biochemical analyses.  Additionally, the BBB in the cuprizone model remains intact, as 
demonstrated by horse radish peroxidase (HRP) tracing and immunohistochemical staining 
for extravasated serum proteins [92, 204, 205].  Likely due to this intact BBB, the cuprizone 
intoxication model also lacks a significant role in T cell immune responses [92, 184, 197].   
RAG-1-/- mice display a phenotypically similar response to cuprizone as wild type mice 
during demyelination and remyelination [49, 93].  Moreover, the infiltration of CD3+ into a 
5-week cuprizone-treated corpus callosum is less than 2 cells/mm2 [92].  In general, the only 
immune cells present in the demyelinated area appear to be microglia/macrophages and 
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astrocytes [190].  Lastly, the temporal and spatial predictability of the cuprizone models 
allows consistent and reliable assessment of remyelination and underlying processes. 
 
Cuprizone-induced Demyelination and Remyelination Time Course in C57BL/6.  As 
mentioned previously, our laboratory has adapted the cuprizone model to the C57BL/6 
mouse [187].  The dose of cuprizone has been titrated to 0.2% , which allows efficient and 
reproducible demyelination of the corpus callosum without systemic toxicity, evidenced by 
liver toxicology [187].  By light microscopy, demyelination can be observed by 3 weeks of 
cuprizone treatment with progression to near-complete demyelination by 5 or 6 weeks; 
however, subsequent experiments suggest full demyelination is reached by week 5 and 
remyelination begins at week 6 [49, 188, 206].  By electron microscopy, observable 
demyelination occurs after 2 weeks of treatment, when oligodendrocyte apoptosis is also 
evident [188, 198].  Similar to previously cuprizone studies, microglia/macrophage and 
astrocyte accumulation was present [185, 187].  Microglia/macrophage accumulation is 
observed as early as 1 week of cuprizone treatment and dramatically increases by 3 weeks, 
with a continual rise through 6 weeks of treatment.  Although 90% of the recruited peripheral 
cells were macrophages, they were far outnumbered by resident microglia, comprising 
approximately 2-4% of the myeloid cells in the corpus callosum [92].  Astrocyte 
accumulation begins by 3 weeks of cuprizone treatment and also continually rises through 6 
weeks [187].  As noted before, although some T cells are observed in brains of cuprizone-
treated mice, the number is negligible compared to the other cellular populations [92].  
Furthermore, studies in RAG-1-/- demonstrate that the absence of T cells does not affect 
cuprizone-induced demyelination or remyelination [49, 93].   
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 In addition to demyelination, studies from our laboratory and others also have defined 
cellular events in the C57BL/6 mice during remyelination upon the removal of cuprizone 
administration.  Oligodendrocyte mRNA patterns, i.e. MAG and myelin oligodendrocyte 
glycoprotein (MOG), in C57BL/6 mice were consistent with previous cuprizone studies [193, 
195, 207].  OPCs could be identified in increased numbers as early as 1 week of cuprizone 
exposure and continually increased and peaked at 4 weeks, when morphological changes 
were observed and were attributed to maturation [198].  Many of these cells were actively 
dividing, as demonstrated by BrdU (5’-bromo-2’-deoxyuridine) incorporation [198].  Mature 
oligodendrocytes re-appear in the demyelinating lesion at 6 weeks, despite continued 
cuprizone administration [198].  Upon removal of cuprizone, the oligodendrocyte population 
continued to repopulate the demyelinated lesion, which was accompanied by increasing 
myelination [198].  Thus, this pattern permits the study of acute demyelination and full 
remyelination or, with continuous administration of cuprizone, a spontaneous but limited 
remyelination first observed at week 6, followed by a second demyelination and then second 
but feeble remyelination observed at week 12 [188].  Afterwards, demyelination ensues and 
the lesion remains permanently demyelinated.  This is presumably due to a lack of OPCs as 
adoptive transfer of OPCs injected into the lesions restores myelination to many of the 
demyelinated fibers (Mason et al, 2004)  
 
Cuprizone Intoxication: A Model for MS-like Lesions.  Multiple sclerosis is a chronic 
inflammatory disease of the CNS that is characterized by large focal lesions or plaques of 
primary demyelination with relative sparing of axons (50-70% reduction of neurite density in 
chronic plaques) [208].  Relapsing-remitting functional impairments in patients are caused 
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mainly from inflammation and demyelination, while the accumulation of irreversible 
neurological deficit is caused mainly by axonal destruction and loss.   
Although MS is widely accepted as an autoimmune disorder, this concept has been 
challenged due to the heterogeneity of MS lesions.  In 2000, Lucchinetti and colleagues 
categorized MS lesions into four patterns based on myelin protein loss, geography and 
extension of plaques, patterns of oligodendrocyte destruction, and immunopathological 
evidence of complement activation (Table 1.1) [209].  In Patterns I and II, lesions are similar 
to those found in EAE with active demyelination mainly associated with T-cell- and 
macrophage-mediated inflammation.  Pattern II is distinctive from Pattern I with 
immunoglobulin and complement deposition (C9neo antigen) at the site of active myelin 
destruction.  Pattern III and IV also contain inflammatory T cells and macrophages in the 
active lesion but are mainly characterized by features that suggest primary loss of 
oligodendrocytes rather than autoimmunity.  Moreover, Pattern III oligodendrocyte loss is 
attributed to apoptosis.  Similar to Pattern III, newly forming lesions in relapsing-remitting 
MS patients exhibit common early structural changes, being extensive oligodendrocyte 
apoptosis and microglial activation [210].  Interestingly, these newly forming lesions had few 
to no T cells.   
Cuprizone intoxication produces lesions that appear similar to Pattern III lesions and 
newly forming lesions with extensive oligodendrocyte cell death, microglial activation, and 
lack of T cell involvement [49, 93, 187, 190].  Although cuprizone is an artificial compound 
and should not be considered a cause of MS, it should be mentioned that other copper 
chelators are present in the environment [190].  Moreover, the cuprizone intoxication model 
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allows the investigation of microglia/macrophage function in demyelination outside the 
context of a T cell immune response.  
 
Cuprizone Studies in Genetic Knockout and Transgenic Mice.  Since adapting the cuprizone 
intoxication model to the C57BL/6 background, a tremendous effort has been made to 
understand underlying processes and mechanisms involved in demyelination and 
remyelination in vivo.  The use of genetic knockout and transgenic mice has been invaluable 
in isolating the contribution of immune molecules, such as cytokines and surface receptors, 
and growth factors to specific roles in a demyelinating lesion and/or a lesion undergoing 
repair.  Several of these studies from our lab and others are summarized below.   
MHCII has been demonstrated to exacerbate demyelination [93].  Moreover, the role 
of MHCII is dependent on an intact cytoplasmic tail.  Mice deficient in MHCII (I-Aβ-/-) or 
mice with a truncated I-Aβ (I-Aβtr), which have intact extracellular and transmembrane 
sequences but lack the cytoplasmic domain, exhibited a delayed demyelination and reduced 
oligodendrocyte apoptosis during demyelination compared to wild type mice.  Furthermore, 
microglia/macrophage accumulation in the corpus callosum of cuprizone-treated mice was 
decreased significantly.  Diminished IL-1β and TNF-α production in the brains of cuprizone-
treated I-Aβ-/- and I-Aβtr mice indicated an attenuated immune response.  Interestingly, MHCII 
also has been demonstrated to be involved in the regeneration of oligodendrocytes and 
subsequent remyelination [23].  I-Aβ-/- mice exhibit a delay in mature oligodendrocyte 
population that is accompanied by a delay in remyelination.  Thus, as with many immune 
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molecules, MHCII appears to play conflicting roles in the demyelinating and repair 
processes.   
Like I-Aβ-/- mice, TNF-α-/- mice exhibit a delay in demyelination and oligodendrocyte 
apoptosis yet also exhibit a delay in remyelination and oligodendrocyte repopulation [49].  
This is likely attributed to the two distinctive signaling pathways mediated through TNFR1 
(p55), which mediates cell death, and TNFR2 (p75), which can either enhance cell death or 
promote cell activation, growth, or proliferation.  Notably, TNF-α is upregulated in MS and, 
thus, was flagged as a potential therapeutic target.  However, upon inhibition of TNF-α, MS 
patients experienced increased relapses and CNS inflammation (The Lenercept Multiple 
Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, 
1999).  This is likely due to the hampering of the beneficial effects of TNF-α. 
LTα is structurally similar to TNF-α and belongs to the TNF superfamily.  LTα-/- mice 
exhibit a delay in demyelination that far exceeds that of TNF-α and is accompanied by a 
delay in oligodendrocyte loss [50].  In contrast to TNF-α-/- mice, LTα-/- mice exhibited 
remyelination that was similar to wild type.  Upon examination of LTβR, the receptor to 
which LTαβ heterotrimer binds, studies demonstrated deletion of the gene resulted in delayed 
demyelination with a slight delay in remyelination [57].  Perplexingly, inhibition of LTβR 
signaling by an LTβR-Ig fusion decoy demonstrated successfully delaying demyelination and 
accelerating remyelination [57].  These studies bode well for targeting LTα as a therapeutic 
agent and for the use of LTβR-Ig as a therapeutic agent in demyelinating disorders.   
 Transgenic mice also have shown the protective effects of immune modulators 
against cuprizone intoxication.  IGF-1Tg/o mice demyelinated with less severity and exhibited 
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a shortened cuprizone-induced demyelination with near-complete recovery by 5 weeks of 
cuprizone treatment [206].  Interestingly, this rapid recovery was attributed to the survival of 
mature oligodendrocyte upon initial cuprizone insult, thus enabling them to restore 
myelination earlier.  This study suggests that IGF-1 is important in prevent oligodendrocyte 
depletion during demyelination. 
The use of genetic knockout and transgenic mice in the cuprizone model has 
elaborated the function of several other genes: iNOS [211], neuronal nitric oxide synthase 
(nNOS) [212], FGF [213, 214], growth arrest-specific 6 (GAS6) [215], CXCR2 [216], 
macrophage inflammatory protein-1α (MIP-1α) [217], leukemia inhibitory factor (LIF) 
[218], TNF-like weak inducer of apoptosis (TWEAK, TNFSF12, Apo3L) [219], PDGF [220, 
221], IFNβ [222], IFNγ [223, 224], acyl-CoA synthetase lipidosin [225], OLIG1/2 [226], p8 
[227], p75NTR [228], Notch1/Jagged1 [229], and osteopontin [230].  Furthermore, this model 
has utility in assessing hormones, as well as drugs and growth factors on prevention of 
demyelination or promotion of remyelination.  Interestingly, a cocktail of PDGF, bFGF, NT-
3 and IGF-1 was injected intracerebroventricularly into cuprizone-treated mice and showed 
increased OPC in the corpus callosum that resulted in greater myelinated fibers [231].   Thus, 
there is an enormous potential of examining currently known factors and yet to be identified 
genes and compounds that may provide insights to basic demyelination and remyelination 
processes, and this model will continue to be invaluable in identifying potential therapeutic 
agents. 
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TABLE 1.1.  Structural and Immunological Features of Different Patterns of Active Multiple 
Sclerosis Lesions. 
 
Values given in cells/mm2. 
Modified from [209]. 
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CHAPTER 2 
 
IL-1α and IL-1β DIFFERENTIALLY AFFECT MATURE OLIGODENDROCYTES 
 
Modified version submitted as: Vivian S. Chen, David D. Chaplin, Yoichiro Iwakura, Glenn 
K. Matsushima.  IL-1α and IL-1β Differentially Affect Mature Oligodendrocytes.  Journal of 
Neuroscience Research. 
 
 
 
2.1  ABSTRACT 
 
 IL-1 is the archetypical proinflammatory cytokine and can be clinically beneficial or 
detrimental in human diseases.  It has been reported to affect many cell types and is 
frequently studied in the context of inflammation.  The IL-1 gene family contains two 
established functional agonists that are closely related in ancestry and structure: IL-1α and 
IL-1β.  IL-1 has been implicated in the pathology of many neurological diseases, such as 
multiple sclerosis.  In the brain, the activation of microglia/macrophages and astrocytes 
results in the production of inflammatory mediators, such as IL-1.  In this study, we 
examined the individual roles of IL-1α and IL-1β and their effects on myelination and 
cellular populations during neurodegeneration and recovery.  After extensive backcrossing of 
IL-1α-/-, IL-1β-/-, and IL-1α-/-β-/- mice onto the C57BL/6 background, we demonstrate that, 
while neither family member affects demyelination or remyelination, an interesting 
phenotype emerged in which IL-1β-/- and IL-1α-/-β-/- mice show reduced numbers of mature 
oligodendrocytes in the corpus callosum, before and after cuprizone treatment. 
 
2.2 INTRODUCTION 
 
 Neuroinflammation is an integral component of demyelinating disease, such as 
multiple sclerosis, and often leads to oligodendrocyte damage and depletion [210].  
Inflammatory cytokines conventionally are believed to contribute to oligodendrocyte death 
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and myelin destruction [232-235]; however, they may also contribute to CNS repair by 
recruitment and differentiation of oligodendrocyte progenitors [49, 57, 236, 237].  Thus, 
there appears to be a subtle balance between inflammation and neuroregeneration.   
The IL-1 gene family contains two functional agonists: IL-1α and IL-1β (reviewed in 
[102]).  Both molecules are synthesized in pro-forms. IL-1α can be active in its pro-form and 
can be cleaved by membrane-associated cysteine protease calpains to an active 17 kDa form.  
ProIL-1β is cleaved by caspase-1 and is only active in its 17 kDa secreted form.  Despite no 
significant differences in the range of activities induced by recombinant IL-1α and IL-1β, the 
two agonists differ in the cellular compartments in which they primarily are active.  IL-1β is 
secreted mainly by monocytes and macrophages but can be secreted by other cell types.  IL-
1α is less abundant in the body, and although it is synthesized in large quantities in cells, 
such as keratinocytes, it appears to be efficiently released only by activated macrophages.  
Although other cell types express cell-associated IL-1α, they do not secrete the 17 kDa form 
unless substantial cell injury occurs.  IL-1α and IL-1β bind a common receptor, IL-1 type I 
receptor, which recruits the IL-1 receptor accessory protein to initiate signal transduction, 
resulting in similar but not completely overlapping responses to the two agonists [102, 238, 
239].   
 In the healthy CNS, IL-1 is expressed at low constitutive levels [114].  Whether this 
endogenous level of IL-1 participates in the physiology of a healthy brain is unknown, as IL-
1α-/- or IL-1β-/- mice appear to develop normally [115, 116].  Upon experimental insult, such 
as ischemia or neurotoxic stimuli, IL-1 expression is quickly upregulated [51, 103, 240-242].  
IL-1 is expressed first by microglia and is followed by astrocytes, infiltrating cells, 
oligodendrocytes, and neurons [128, 129, 243].  It remains debatable whether this IL-1 
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response is involved in neurodegeneration or as part of an inflammatory response to resolve 
the insult. The differential roles of IL-1α and IL-1β in the context of disease has become 
more prominent with the development of IL-1 knockout mice: IL-1α-/-, IL-1β-/- and IL-1α-/-β-/- 
mice [115, 116].  To address the roles of IL-1α and IL-1β in demyelination and 
remyelination, we applied the cuprizone intoxication model, which allows the analysis of 
neuroinflammation, demyelination, and remyelination in a predictable time course and 
pattern, to these knockout mice [183, 184, 187, 190, 195].  Previously, our lab published that 
IL-1β-/- mice display a delay in remyelination, resulting from a delay in mature 
oligodendrocyte repopulation [51].  Since our initial report, we have backcrossed the IL-1β-/- 
strain further onto the C57BL/6 background.  In this study, we report a phenotypic change in 
these backcrossed mice in which there are inherently fewer mature oligodendrocytes.  
Additionally, we characterize the role of IL-1α in cuprizone-induced demyelination and 
remyelination. 
 
2.3 MATERIALS AND METHODS 
 
Mice.  All mice were housed in a pathogen-free facility and were maintained in accordance 
with NIH guidelines and approved protocols by the University of North Carolina Institutional 
Animal Care and Use Committee and the University of North Carolina Division of 
Laboratory Animal Medicine.  C57BL/6 mice were either purchased from Jackson 
Laboratories (Bar Harbor, ME) or bred in-house at the UNC animal facility.  IL-1β-/- mice on 
the C57BL/6 background [116] were obtained from Dr. David D. Chaplin (University of 
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Alabama at Birmingham) and were backcrossed further onto our in-house C57BL/6 
background (N>6), originally obtained from Jackson Laboratories.  IL-1α-/- and IL-1α-/-β-/- 
mice [115] were obtained from Dr. Yoichiro Iwakura (The Institute of Medical Science, The 
University of Tokyo) and bred onto our in-house C57BL/6 background (N>6).  C57BL/6 
mice hemizygous for the green fluorescent protein (GFP) gene under the control of the 
chicken β-actin promoter and cytomegalovirus (CMV) enhancer were bred in-house with 
wild type C57BL/6 mice (C57BL/6 GFPTg/o, N>12).  These GFP transgenic mice were 
originally obtained from Jackson Laboratories, and their generation and breeding have been 
previously described [244, 245].   
 
 Bone Marrow Transplant and Flow Cytometric Analysis of Bone Marrow Engraftment.  
Methods for bone marrow transplants have been previously modified and described [92].  
Briefly, C57BL/6 GFPTg/o and  IL-1β-/- GFPTg/o chimeras were generated by lethal irradiation 
of 4-5 week old C57BL/6 or IL-1β-/- male mice with a total of 800 cGy at a dose rate of 50 
cGy/minute using a 60Co γ irradiator (Atomic Energy of Canada, Kanata, Ontario).  
Following overnight recovery, the irradiated mice were injected intravenously through the 
tail vein with 3-5 x 107 bone marrow cells flushed and isolated from the femurs and tibias of 
donor C57BL/6 GFPTg/o male mice as previously described [92, 246].  No antibiotic 
treatment was given and animal mortality from bacterial infections after irradiation did not 
occur.  Animals were allowed to reconstitute for 4 weeks.  PBMCs were isolated as described 
previously for flow cytometric analysis to check for near to complete reconstitution before 
beginning cuprizone treatment [92, 246]. 
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Cuprizone Treatment.  8-10 week old male mice that were approximately 25 grams were fed 
0.2% (w/w) cuprizone (Sigma, St. Louis, MO) mixed in ground rodent chow (ProLab IsoPro 
RMH 3000, LabDiet, Brentwood, MO) for up to 6 weeks to induce demyelination [187].  At 
6 weeks of treatment when remyelination begins, the mice were returned to a normal diet.  
Untreated male mice were maintained on normal diet for the duration of the experiment. 
 
Tissue Preparation.  Mice were perfused intracardially with 0.15 M phosphate buffer , pH 
7.4, [247] for 1 minute followed by 4% paraformaldehyde (PFA) in phosphate buffer for 8 
minutes.  Brains were removed and postfixed in 4% PFA for a minimum of 24 hours at 4°C 
before processing and embedding by the UNC Lineberger Comprehensive Cancer Center 
Histopathology Core.  Five-micron coronal sections of the corpus callosum at midline 
between region 220 and 260 of the Atlas of the Mouse Brain and Spinal Cord were used for 
histology and immunohistochemistry [248].  
 
Luxol Fast Blue-Periodic Acid Schiff’s Staining.  Paraffin sections were stained with a Luxol 
fast blue-periodic acid Schiff (LFB-PAS) stain as previously described [187].  Myelination 
was scored on a scale of 0 to 3.  For myelination, a score of 0 was equivalent to no 
myelinated axons in the demyelinated region, and a score of 3 was indicative of full 
myelination.   
 
47 
 
Transmission Electron Microscopy. Mice were perfused intracardially with 0.15 M 
phosphate buffer [247] for 1 minute followed by 4% PFA and 2.5% glutaraldehyde in 
phosphate buffer for 10 minutes.  Mice were postfixed in 4% PFA and 2.5% glutaraldehyde 
for a minimum of 2 weeks.  The region of the corpus callosum corresponding to the region in 
sections 220-260 of the Sidman mouse brain atlas was cross-sectioned and stained in partial 
collaboration with Clarita Langaman and the UNC Microscopy Services Laboratory.  
Corpora callosa were analyzed using Image-Pro Plus v.5.0.2.9 (Media Cybernetics, Inc., 
Bethesda, MD).  A minimum of five micrographs per mouse were quantified for the number 
of myelinated and unmyelinated axons.  Axons below 0.3 μm in diameter are rarely 
myelinated and were excluded.  Each treatment group contained a minimum of three mice. 
 
Immunohistochemistry and Lectin Staining.  Paraffin sections were deparaffinized with 
Histo-Clear (National Diagnostics, Atlanta, GA) and rehydrated through a series of graded 
ethanols.  GSTpi immunohistochemistry was performed to identify mature oligodendrocytes 
as described previously [51].  Briefly, sections were blocked and permeabilized in 2% 
normal goat serum (NGS) and 0.1% Triton X-100 in PBS for 30 minutes at room temperature 
and then unmasked with 0.1% trypsin in a 50 mM Tris solution (pH 7.4) for 15 minutes at 
37°C.  Sections were then incubated with rabbit anti-GSTpi antibody (1:1000, Biotrin, USA) 
for overnight at 4°C.  Tissues were rinsed and incubated with Alexa Fluor goat anti-rabbit 
IgG (1:400, Invitrogen/Molecular Probes).   Apoptosis was determined by In Situ Cell Death 
Detection, Fluorescein (Roche Applied Science, Indianapolis, IN).  Ricinus communis 
agglutin-1 (RCA-1) lectin stain was performed to identify microglia/macrophages as 
described previously [187].  Briefly, sections were unmasked with 0.025% protease, type 
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XIV (Sigma) for 2 min at 43˚C, blocked and permeabilized with 5% bovine serum albumin 
(BSA) and 0.1% Triton X-100 in phosphate buffered saline (PBS), and incubated with 
biotinylated RCA-1 (1:500, Vector, Burlingame, CA) for overnight at 4°C.  Slides were 
washed and incubated with Alexa Fluor Strepavidin (Invitrogen/Molecular Probes).  GFAP 
immunohistochemistry was performed to identify astrocytes as previously described [187].  
Briefly, sections were blocked and permeabilized in 2% NGS and 0.1% Triton X-100 in PBS 
for 30 minutes.  Sections were incubated in rat anti-GFAP antibody (1:400, 
EMD/Calbiochem, San Diego, CA) for overnight at 4°C.  Tissues were then washed and 
incubated with Alexa Fluor goat anti-rat IgG (1:400 Invitrogen/Molecular Probes).  All slides 
were mounted in Vectashield HardSet with DAPI (Vector) in order to visualize nuclei. 
Image-Pro Plus was used to count and calculate cells per mm2 from digital images.  
Quantification included cells in which a nucleus was colocalized with immunohistochemical 
staining. 
 
Statistics.  Data are expressed as mean ± SEM.  Multiple comparisons were evaluated using a 
two-tailed Student’s t-test.  Differences were considered statistically significant if p  0.05. 
  
2.4 RESULTS 
 
IL-1β-/- mice lost their previously characterized myelination phenotype after extensive 
backcrossing to C57BL/6.  IL-1β-/- mice were previously characterized to display a 
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demyelination phenotype similar to wild type mice during cuprizone-intoxication yet a 
delayed or impaired ability to remyelinate upon discontinuation of cuprizone treatment [51].  
Moreover, our laboratory has demonstrated that 90% of recruited myeloid cells to the corpus 
callosum in cuprizone-treated mice are microglia and approximately 4% are peripheral 
macrophages [92].  Because cuprizone-induced demyelination is characterized by a robust 
microglia/macrophage response, our objective at first was to determine whether 
microglia/macrophages, in terms of IL-1β production, play an important role in promoting 
remyelination of the CNS [92, 187].  Four- to five-week old IL-1β-/- mice and wild type 
controls were lethally irradiated and subsequently received bone marrow transfers from 
GFPTg/o mice.  Four weeks later, bone marrow engraftment was measured by flow cytometry 
of PBMCs.  While background fluorescence was minimal in C57BL/6 mice (1%), 80% of the 
PBMCs were GFP+ in the GFPTg/o mice.  In the chimeric mice, 83% of the PBMCs were 
GFP+ (data not shown).  With cuprizone treatment C57BL/6 GFPTg/o and IL-1β-/- GFPTg/o 
chimeras demyelinated almost completely by 5 weeks, 4% and 3% respectively, assessed by 
transmission electron microscopy (Figure 2.1A).  Likewise, C57BL/6 and IL-1β-/- mice that 
did not receive bone marrow transfers demyelinated almost completely, to levels of 5% and 4 
% respectively (Figure 2.1A).  After 2 weeks of discontinued cuprizone treatment, C57BL/6 
and IL-1β-/- mice that did not receive bone marrow transfers appeared to recover fully and 
equally (Figure 2.1A).  These mice alone suggest a loss of the remyelination phenotype 
found originally in the IL-1β-/- mice (Mason, 2001b).  Thus, it was not a surprise that, despite 
a delayed remyelination compared to mice that did not receive bone marrow transfers, both 
chimeras also remyelinated equally (Figures 2.1A-C).  It should be noted that these IL-1β-/- 
mice used here were further backcrossed onto the C57BL6/J background and genes that may 
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have contributed to the original phenotype appear to have been removed by recombination 
events.  Whether macrophages/microglia production of  IL-1β is important to the promotion 
of remyelination in the CNS remains inconclusive.   
 
 IL-1 does not affect cuprizone-induced demyelination and remyelination. In addition to the 
IL-1β-/- mice, two other strains of mice were obtained from Dr. Yoichiro Iwakura: IL-1α-/- 
mice and IL-1α-/-β-/- mice.  The role of IL-1α was examined in the cuprizone model, in 
addition to the re-examination of IL-1β.  8-10 week old mice were placed on the cuprizone 
diet for up to 6 weeks.  Maximum demyelination is known to occur after 5 weeks of 
treatment, during which time remyelination spontaneously begins to occur and continues 
upon removal of cuprizone from the diet.  Myelination of the corpus callosum at midline was 
examined by LFB-PAS stain.  Myelinated fibers stained blue, and unmyelinated fibers 
stained pink.  The sections were blind scored on a scale from 0 to 3, in which 0 is 
representative of complete demyelination and 3 is reflective of full myelination.  All strains 
appeared to demyelinate fully and remyelinate at a similar rate (Figure 2.2). 
 
IL-1 does not affect mature oligodendrocyte apoptosis.  The absence of IL-1 did not alter the 
number of apoptotic GST-pi+ mature oligodendrocytes during demyelination.  The death of 
mature oligodendrocytes peak at week 3 and results in the ongoing demyelination until week 
5.  IL-1 has been implicated in the death of oligodendrocytes in vitro (Merrill 1991); however 
as shown in Figure 2.3, IL-1α-/-, IL-1β-/-, IL-1α-/-β-/- mice showed similar amounts of 
apoptotic mature oligodendrocytes as wild type animals at week 3.  A slight amount of 
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apoptotic mature oligodendrocytes were detected at week 4 and at week 5; however, these 
were not statistically significant.  Thus, it appears that IL-1 does not contribute importantly to 
the apoptosis of mature oligodendrocytes.  It is possible that other mediators, such as TNF-α 
or NO, may compensate for the loss of IL-1 [49, 211]. 
 
IL-1 does not affect the accumulation or the resolution of the microglia/macrophage 
population in the corpus callosum during cuprizone-induced demyelination or remyelination.  
With the exposure to cuprizone and the death of mature oligodendrocytes, microglia 
accumulate within the corpus callosum presumably to clear dying cells and debris.  In 
addition, microglia are important for providing growth factors and cytokines, including IGF-
1 and TNF-α [49, 198].  To determine whether the absence of IL-1 affected the microglial 
populations, we quantified microglia accumulation at key time points during demyelination 
and remyelination.  RCA-1 is a lectin that is used to identify microglia/macrophages by 
histochemical analysis.  RCA-1+ cells in the midline of the corpus callosum were enumerated 
for individual mice and averaged for each treatment group.  The results do not indicate a 
significant difference in the accumulation of this cell population in absence of IL-1α and/or 
IL-1β (Figure 2.4) at any time point.  During remyelination the microglia/macrophage 
population diminishes similarly in all of the knockout strains, as well as wild type mice 
(Figure 2.4). 
 
IL-1 does not affect astrogliosis or resolution of the astrocyte population in the corpus 
callosum during cuprizone-induced demyelination or remyelination.  A second prominent 
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source of IL-1 during demyelination is astrocytes, which accumulate in moderate numbers 
and are present throughout remyelination [51, 187, 198].  GFAP is the astrocyte marker used 
for immunohistochemical analysis in this report.  GFAP+ cells were counted in the midline of 
the corpus callosum for individual mice and averaged for each treatment group.  The data 
show no significant differences in the accumulation of astrocytes in the corpus callosum in 
the absence of IL-1β and/or IL-1α (Figure 2.5).  Moreover, there are no significant 
differences in the diminishing population during remyelination (Figure 2.5). 
 
IL-1β affects the mature oligodendrocyte population in untreated and remyelinated corpus 
callosum.  Although we did not observe differences in demyelination or remyelination 
among the IL-1 genotypes (Figure 2.1), we quantified the mature oligodendrocyte population 
as done previously in the published characterization of the  IL-1β-/- mice, which showed a 
delay in the repopulation of the demyelinated corpus callosum [51].  GSTpi 
immunohistochemistry was performed to identify mature oligodendrocytes in wild type, IL-
1β-/-, IL-1α-/-, and IL-1α-/-β-/- mice during cuprizone-induced demyelination and 
remyelination.  GSTpi+ cells were enumerated at the midline of the corpus callosum for 
individual mice and averaged for each treatment group.  Interestingly, in untreated mice, IL-
1β-/- displayed a significant deficit in the number of mature oligodendrocytes compared to 
wild type, while the absence of IL-1α appeared to have no effect (Figures 2.6A, B).  
Although more subtle, the IL-1α-/-β-/- mice also displayed a significant deficit in the number 
of mature oligodendrocytes and showed an intermediate phenotype between the IL-1α-/- mice 
and IL-1β-/- mice (Figures 2.6A, B).  During demyelination the number of mature 
oligodendrocytes dying by apoptosis, as demonstrated by co-staining with terminal 
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deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL), is similar in all strains, 
indicating a comparable insult by cuprizone (Figure 2.3).  At 5 weeks, which coincides with 
full demyelination, few mature oligodendrocytes are found in the lesion.  Upon 
remyelination, mature oligodendrocytes in IL-1β-/- mice repopulate to untreated levels after 1 
week of discontinued cuprizone treatment.  Furthermore, 4 weeks after cuprizone removal, 
mature oligodendrocyte populations in all strains reflect similar numbers in untreated mice 
(Figures 2.6A, B).  Inherently, IL-1β-/- mice have fewer mature oligodendrocytes before 
cuprizone insult and, upon remyelination, repopulate to their original numbers that is lower 
than wild type mice and IL-1α-/- mice.  Moreover, IL-1α-/-β-/- mice displayed an intermediate 
phenotype between IL-1α-/- mice and IL-1β-/- mice.  NG2+ immature oligodendrocytes were 
examined during demyelination at 5 weeks, and the number of immature oligodendrocytes 
did not differ significantly (data not shown), indicating that infiltration of NG2+ cells is not 
affected by IL-1β.  Thus, IL-1β appears to affect the number of oligodendrocytes within the 
corpus callosum despite myelination of axons appearing normal (Figure 2.1C compared to 
Figure 2.1B).   
 
2.5 DISCUSSION 
 
 The results from our study indicate that IL-1α and IL-1β are not important mediators 
of cuprizone-induced demyelination or remyelination (Figures 2.1, 2.2).  This supports our 
previously published assertion that IL-1, in its proinflammatory role, does not exacerbate 
demyelination [51].  Although the initial insult to oligodendrocytes in our model is toxicity, 
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we demonstrate that IL-1α and/or IL-1β neither enhances nor reduces oligodendrocyte 
apoptosis, as these cells are similarly affected in wild type, IL-1α-/-, IL-1β-/-, and IL-1α-/-β-/- 
mice (Figure 2.3).  Because IL-1 does not appear to be enhancing oligodendrocyte apoptosis, 
it may play a protective role for oligodendrocytes during insult, which is contrary to in vitro 
data suggesting IL-1 is detrimental to oligodendrocytes [249].  We, however, have found a 
novel and inherent difference in the mature oligodendrocyte population in the IL-1β-/- and IL-
1α-/-β-/- mice compared to wild type mice.  IL-1β-/- mice have significantly fewer mature 
oligodendrocytes in the corpus callosum compared to wild type mice prior to cuprizone 
treatment, and the effect that the lack of IL-1β has on this population can also be seen in the 
IL-1α-/-β-/- mice, albeit more subtly (Figure 2.6).   Moreover, this inherent difference in 
number is restored upon remyelination, with IL-1β-/- mice fully repopulating to untreated 
levels after 1 week of cuprizone removal and IL-1α-/-β-/- mice fully repopulating to untreated 
levels after 4 weeks of cuprizone removal.  The significance of this oligodendrocyte effect is 
underscored by the fact that the IL-1β-/- and the IL-1α-/-β-/- strains, the two IL-1 targeted 
strains that show this phenotype, were originally generated in laboratories at Washington 
University in the USA and at the University of Tokyo in Japan, respectively, and only 
became apparent after extensive backcrossing to the C57BL/6 strain.  The fact that this 
phenotype was not observed in IL-1α-/- mice that were subjected to the same backcrossing 
effectively makes the possibility that the IL-1β effect is due to confounding strain genetic 
background issues less likely.  Our observations may suggest IL-1β is needed for the 
establishment of the oligodendrocyte population and is consistent with in vitro studies that 
report IL-1β promotes maturation and survival of differentiating oligodendrocytes [142].  
Thus, in the absence of IL-1β, fewer oligodendrocytes mature.  Although both the IL-1β-/- 
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and IL-1α-/-β-/- mice have this deficit in oligodendrocyte numbers, myelination appears to be 
consistent with both wild type and IL-1α-/- mice (Figures 2.6A, 2.2).  This may be explained 
by more complex arborization and myelinating processes per oligodendrocyte in the mice 
lacking IL-1β.  This hypothesis was tested by examining mature proteolipid protein (PLP)-
expressing oligodendrocytes in the corpus callosum of untreated wild type PLP-EGFP mice 
and PLP-EGFP mice backcrossed onto the IL-1β-/- background (data not shown).  Although 
there appeared to be fewer PLP-expressing oligodendrocytes in the corpus callosum, 
examination of the arborization was inconclusive due to the compact nature of a fully 
myelinated corpus callosum that prevented quantification. 
Studies indicate that upon CNS insult, immune mediators, such as IL-1, activate 
microglia and result in proliferation and/or infiltration [249].  Surprisingly but consistent 
with previously published data from our lab, accumulation of microglia/macrophages in IL-
1β-/- mice during cuprizone intoxication was not significantly different from wild type mice 
upon exposure to cuprizone (Figure 2.4).  Additionally, the IL-1α-/- and IL-1α-/-β-/- mice 
behaved similarly, indicating that the microglia/macrophage proliferation and/or infiltration 
were neither IL-1α-dependent nor IL-1β-dependent (Figure 2.4).  As demonstrated for 
microglia/macrophages, it has been shown that astrocytes produce IL-1β in our cuprizone-
intoxication model [51].  Similar to the microglia/macrophage population and despite their 
role in IL-1 production, their migration and proliferation in the demyelinating lesion is not 
dependent on IL-1α or IL-1β (Figure 2.5). 
 Despite signaling through the same receptor, namely IL-1RI, IL-1β is often studied 
for its proinflammatory effects, while IL-1α is just as often overlooked.  Admittedly, the two 
molecules are differentially expressed on a subcellular level.  IL-1β is only active in its 
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mature, 17 kDa form and is released from phagocytic cells in association with activation of 
caspase-1 and the newly defined inflammasome [105].  In contrast, IL-1α can be active in 
both its pro-form and its mature, 17kDa form, and for the most part remains intracellular or 
cell-associated.  However, although it is clear that in the process of cell death, IL-1α is 
readily released from the cell [102], there is emerging evidence that IL-1α can also be 
released from cells as a consequence of non-lethal cell injury, also by a caspase-1-dependent 
mechanism [105].  In cases involving a CNS insult, whether by damage or toxin, it is feasible 
that IL-1α contributes to the inflammatory processes.  In our cuprizone model, IL-1 is 
upregulated upon intoxication [198].  The data we report here demonstrates that, while 
neither isoform of this cytokine appears to be essential for either the demyelination or the 
remyelination process, IL-1β, as shown through analysis of IL-1β-/- and IL-1α-/-β-/- mice, does 
play a contributory role in the establishment of mature oligodendrocyte populations.   
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FIGURE 2.1.  Bone marrow transfers from donor GFPTg/o (C57BL6) mice into recipient IL-
1β-/- mice does not rescue a lacking phenotype.  (A)  Quantification of percent myelination 
by transmission electron microscopy reveals a loss of a previously characterized myelination 
phenotype.  Wild type (C57BL6) and IL-1β-/- mice demyelinated and remyelinated similarly 
upon delivery and removal of cuprizone, respectively.  Wild type and IL-1β-/- mice that were 
irradiated and reconstituted with wild type EGFP also remyelinated similarly.  (B) 
Representative micrograph of EGFP/C57BL6 chimeras at (6+2) weeks.  Average 
myelination for n=4 was 41.5%.  (C) Representative micrograph of EGFP/IL-1β-/- chimeras 
at (6+2) weeks.  Average myelination for n=3 was 39.7%.  Scale bar is 2 μM.  
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FIGURE 2.1 
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FIGURE 2.2.  IL-1 does not affect cuprizone-induced demyelination or remyelination.  
Tissues were stained by LFB-PAS and scored on a scale from 0 to 3 in which a score of 0 
represents full demyelination and 3 represents full myelination.  The midline of the corpus 
callosum from a minimum of eight mice for each treatment group were scored and averaged.  
Bars represent average ± SEM. 
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FIGURE 2.2 
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FIGURE 2.3.  Exposure to cuprizone does not differentially affect mature oligodendrocyte 
death in IL-1-/- mice and wild type mice.  Apoptotic GSTpi+ cells at the midline of the corpus 
callosum were counted at time points during demyelination and averaged.  No statistical 
differences were observed.  Bars represent average ± SEM.   
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FIGURE 2.3 
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FIGURE 2.4.  Microglia/macrophage infiltration and exit are not affected by IL-1 during 
cuprizone-induced demyelination and remyelination.  RCA-1+ cells were counted at the 
midline of the corpus callosum from a minimum of eight mice for each treatment group and 
averaged.  Bars represent average ± SEM. 
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FIGURE 2.4 
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FIGURE 2.5.  Astrogliosis and astrocyte resolution are not affected by IL-1 during 
cuprizone-induced demyelination and remyelination.  GFAP+ cells were counted at the 
midline of the corpus callosum from a minimum of eight mice for each treatment group and 
averaged.  Bars represent average ± SEM. 
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FIGURE 2.5 
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FIGURE 2.6.  IL-1β affects the number of mature oligodendrocytes before cuprizone 
treatment and after remyelination.  (A) GSTpi+ cells were counted at the midline of the 
corpus callosum from a minimum of eight mice for each treatment group and averaged.  Bars 
represent average ± SEM.  *p ≤ 0.05 (B) Representative images of GSTpi+ cells at the 
midline of the corpus callosum of C57BL/6, IL-1β-/-, IL-1α-/-, and IL-1α-/-β-/- mice at the (0+0) 
and (6+4) time points.  Scale bar is 20 μm.  
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FIGURE 2.6 
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CHAPTER 3 
 
THE ROLE OF LAG-3 IN CUPRIZONE INDUCED DEMYELINATION AND 
REMYELINATION 
 
 
3.1  ABSTRACT 
 
LAG-3 is a membrane-bound glycoprotein that shares many structural similarities to 
CD4.  It was originally identified on the surface of activated T cells where it has been shown 
to be involved in negative regulation of activity and clonal expansion through its interaction 
with MHCII.  Despite an apparent insignificant role of T cells in the cuprizone intoxication 
model, we demonstrate elevated LAG-3 gene and protein expression in response to cuprizone 
insult.   Moreover, we demonstrate a previously undescribed location of LAG-3 expression 
on OPCs and astrocytes.  To examine the function of LAG-3, we expose LAG-3-/- mice to 
cuprizone and assessed demyelination and remyelination. We find that demyelination is 
accelerated in LAG-3-/- mice and that a greater number of OPCs and astrocytes are present in 
the corpus callosum at week 3 of cuprizone treatment.  However, a greater proliferation of 
OPCs was observed in the SVZ of LAG-3-/- mice and not the corpus callosum, suggesting 
that the majority of OPCS divide first and then migrate to the corpus callosum in greater 
numbers.  We did not observe, however, a significant difference in remyelination.  Although 
LAG-3 was not found on microglia, their numbers were increased in LAG-3-/- mice at week 3 
of cuprizone treatment, and this may be attributed to the rapid demyelination observed.  We 
also examined OPCs in mixed glial cultures and found that LAG3+ OPCs engaged MHCII 
tetramers, suggesting OPCs may engage MHCII directly and presumably limit expansion and 
trigger differentiation of the OPCs.  Thus, we are the first to demonstrate LAG-3 expression 
on  glial cells and deduce that the function of LAG-3 is to regulate OPC and astrocyte 
populations prior to repair of demyelinating lesions. 
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3.2 INTRODUCTION 
 
LAG-3 is an activation-induced TCR coreceptor that binds MHCII [155, 156, 159, 
250].  It was first identified on activated human NK cells and T lymphocytes; more recently, 
it has been identified on activated B cells [155, 156, 158].  LAG-3 has been shown to be 
closely related to CD4 in genomic organization and structure [155, 251, 252].  Much of the 
initial characterization of LAG-3 was focused on the human protein.  However, with the 
development of LAG-3-/- mice, in vitro findings can be validated in a physiological setting 
[253].  Murine LAG-3 displays 69.9% protein sequence homology to the human homologue 
and possesses the residues that are putatively important to structure [169].  It can be found in 
three forms: 70kD full length, and a 54kD and a 16kD fragment that is soluble [254].   
LAG-3 serves as a two-way signaling molecule, affecting the cell that expresses 
LAG-3 and the APC that it engages.  As mentioned before, LAG-3 binds MHCII, and it does 
this with much higher avidity than CD4, suggesting a role as a natural competitor to CD4 
[159].    On T lymphocytes, LAG-3 associates with the CD3/TCR complex and negatively 
regulates signal transduction and antigen-driven T cell expansion [160, 161, 170, 175, 255].  
While LAG-3 seemingly has a negative regulatory effect on the cell that expresses it, LAG-3 
has the capacity to activate APCs via MHCII.  Experimental studies demonstrate that LAG-3 
and MHCII are strongly upregulated during inflammation [164].  In response to ligation of 
soluble LAG-3 (sLAG-3)-Ig fusion protein to MHCII, monocytes and dendritic cells are 
stimulated for the production of TNF-α and IL-12 [164].  Moreover, T cell-activation of 
monocytes is suppressed effectively by LAG-3-specific antibodies [164].  sLAG-3-Ig fusion 
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protein also has been shown to induce dendritic cell maturation and migration to secondary 
lymphoid organs to prime CD4+ and CD8+ T cells [162, 164, 256].  In contrast, another study 
suggests sLAG-3 may play a role in negatively regulating monocyte differentiation into 
macrophages or fully competent antigen-presenting dendritic cells in vitro [257].  Lastly, a 
role of LAG-3 in regulatory T cells has been suggested.  A recent study shows regulatory T 
cells expressing LAG-3 suppress dendritic cell maturation and immunostimulatory capacity 
via engagement with MHCII, resulting in ITAM-mediated inhibitory signaling that involves 
FcγRγ  and Erk-mediated recruitment of SHP-1 [258].   
 The distribution of murine LAG-3 mRNA expression shows strong expression in the 
thymus and spleen [157].  Interestingly, there was also a significant amount of message in the 
brain, which appeared to differ with the maturational state of the animal.  In postnatal day 7 
mouse brain, LAG-3 mRNA was detected in defined tracts at the base of the cerebellum and 
in the choroids plexus.  In contrast, in the adult brain, LAG-3 mRNA was detected, but only 
in areas outside of the cerebellum.  A similar study in the rat revealed a slightly expanded 
distribution with LAG-3 message also appearing in the lung, liver and small intestine, and 
again, there was also strong message in the brain tissue [172].  Most of the tissues in which 
LAG-3 message was identified in mouse and rat contain either large numbers of circulating 
lymphocytes, which easily explains the presence of LAG-3 message. The healthy brain, 
however, contains negligible numbers of these cells and so the expression of LAG-3 here 
must be attributed to some other cell type.  Despite these reports of LAG-3 in the developing 
and adult brain, there have been few studies investigating the role of LAG-3 function in the 
central nervous system (CNS) [157, 172].  Although LAG-3 has thus far been characterized 
solely as an immune mediator, several molecules that were previously thought to be utilized 
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exclusively by the immune system, most notably MHC I and CD3ζ, have since been found to 
be important in development of the CNS [259, 260].  
 In this study, we examined the function of LAG-3 during CNS insult.  We used the 
cuprizone intoxication model, which allows the analysis of neuroinflammation, 
demyelination, and remyelination in a predictable time course and pattern [183, 184, 187, 
190, 195, 198].  With cuprizone treatment of C57BL/6 mice, perturbation and mature 
oligodendrocyte cell death are followed by microglia/macrophage infiltration, astrogliosis, 
and substantial demyelination by 5 weeks [190].  Concurrently, oligodendrocyte progenitors 
begin to populate the demyelinating lesion after 3 weeks of treatment and differentiate into 
mature oligodendrocytes during remyelination beginning at week 6 [188, 195, 198].  
Interestingly, T cells do not play a significant role during cuprizone-intoxication and/or 
amelioration [49, 92, 93].  RAG-1-/- do not display phenotypic differences in demyelination, 
remyelination, or cellular populations throughout the cuprizone time course [49, 93].  Despite 
the lack of T cell participation in our model, we demonstrate a substantial increase in LAG-3 
gene and protein expression during cuprizone intoxication.  Moreover, in this study, we 
report novel localization of LAG-3 to immature oligodendrocytes and astrocytes, as well as 
the role of LAG-3 during demyelination and remyelination. 
 
3.3 MATERIALS AND METHODS 
 
Mice.  All mice were maintained in a pathogen-free facility in accordance with NIH 
guidelines and approved protocols by the University of North Carolina Institutional Animal 
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Care and Use Committee and the University of North Carolina Division of Laboratory 
Animal Medicine.  C57BL/6 mice were either purchased from Jackson Laboratories (Bar 
Harbor, ME) or bred in-house at the UNC animal facility.  LAG-3-/- mice on the C57BL/6 
background were obtained from Dr. Dario A. Vignali (St. Jude Children's Research Hospital, 
Memphis, TN).  PLP promoter-driver enhanced GFP transgenic mice (PLP-EGFPTg/o) were 
obtained from Dr. Wendy B. Macklin (Lerner Research Institute, Cleveland Clinic 
Foundation, Cleveland, OH) [79]. 
  
Cuprizone Treatment.  8-10 week old male mice that were approximately 25 grams were fed 
ad libitum a diet consisting of 0.2% (w/w) cuprizone (bis-cyclohexanone oxaldihydrazone, 
Sigma-Aldrich, St. Louis, MO) mixed in ground rodent chow (ProLab IsoPro RMH 3000, 
LabDiet, Brentwood, MO) for up to 6 weeks to induce demyelination (Hiremath et al. 1998).  
For remyelination, the mice were returned to a normal diet after 6 weeks of treatment.  
Untreated control mice were maintained on normal diet for the duration of the experiment. 
 
Microarray analysis.  Affymetrix GeneChip arrays (Affymetrix, Santa Clara, CA) were used 
to profile gene expression.  Corpus callosum was dissected from three mice at 0-6, 8, 10, and 
12 weeks from a cuprizone time course.  Total RNA was harvested using Trizol (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instruction and was given to the UNC 
Neuroscience Center Functional Genomics Core for further processing: cDNA synthesis, in 
vitro transcription, RNA cleanup, hybridization, washing, and scanning of the microarray 
with GCOS v1.4 (Affymetrix).  The mouse genome U74Av2, containing gene probes for 
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~6000 genes and ~6000 expressed sequence tags clusters in the Mouse Unigene database, 
were used for this experiment.  Genespring software (GenUs Biosystems, Inc., Northbrook, 
IL) was used to generate data presented.  This experiment was repeated to lend greater 
fidelity to the data. 
 
In situ hybridization.  LAG-3 in situ hybridization was modified from methods previously 
described [157] and done in collaboration with Dr. Yongqin Wu of the UNC Neuroscience 
Center In Situ Hybridization Core Facility.  Modification of methods replaced sense and 
antisense [32P]UTP-labeled riboprobes with digoxigenin-labeled oligonucleotide probes.  
 
Western blot.  Corpus callosum was dissected from three mice at 0-5, 7, 8, and 10weeks from 
a cuprizone time course.  Tissue was dissociated with 3 quick pulses at an amplitude of 60% 
at 4°C using the Sonic Dismembrator (Model 500, Fisher Scientific) in RIPA buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium 
deoxycholate, 1 mM PMSF, 2.5 μg/ml aprotinin, 2.5 μg/ml leupeptin, 1 μM pepstatin A; 
Sigma-Aldrich).  Lysates were cleared by centrifugation.  SDS sample-loading buffer was 
added to each sample, and the sample was boiled and resolved on a SDS-PAGE gel.  Proteins 
were transferred onto polyvinylidene difluoride membrane (Millipore, Billerica, MA) and 
blotted in 5% milk-TBS with 0.1% Tween 20 (TBS-T) for 30 min.  Anti-LAG-3 (rabbit 
polyclonal serum against the D1 domain of LAG-3 gifted by Dr. Dario A. Vignali) was used 
at 1:500 in 2.5% milk-TBS-T for overnight incubation at 4°C.  Blots were washed in TBS-T 
and incubated in anti-rabbit-HRP antibody (Vector Laboratories, Burlingame, CA) at 
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1:10,000 in 2.5% milk-TBS-T for 1 h followed by further washing in TBS-T. Blots were 
incubated with ECL-Plus (GE Healthcare, Piscataway, NJ) and visualized using HyBlot CL 
autoradiography film (Denville Scientific, Metuchen, NJ). 
 
Bromodeoxyuridine incorporation.  Oligodendrocyte expansion was determined by injecting 
100 mg/kg BrdU (Sigma) in phosphate-buffered saline (PBS) into the peritoneal cavity of 
experimental mice every 8 hours for two days. 
 
Tissue Preparation.  Mice were anesthetized with Isoflurane (Vedco, St. Joseph, MO) and 
perfused intracardially with 0.15 M phosphate buffer, pH 7.4, [247] for 1 minute followed by 
4% PFA in phosphate buffer for 8 minutes.  For paraffin-embedded tissues, brains were 
postfixed in 4% PFA for 24 hours at 4°C before processing and embedding by the UNC 
Lineberger Comprehensive Cancer Center Histopathology Core.  Coronal sections, 5 μm in 
thickness, of the corpus callosum at midline between region 220 and 260 of the Atlas of the 
Mouse Brain and Spinal Cord [248] were cut and mounted on VWR Superfrost Plus Micro 
slides (West Chester, PA) for histology and immunohistochemistry.  For fixed frozen tissues, 
brains were postfixed in 4% PFA for 4 hours or overnight before transferring to 30% sucrose 
for overnight at 4°C.  Tissues were then embedded using OCT media (Fisher Scientific, 
Fairlawn, NJ).  Coronal sections, 7 μm in thickness, of the corpus callosum at midline 
between region 220 and 260 of the Sidman mouse brain atlas were cut and mounted on VWR 
Superfrost Plus Micro slides for immunohistochemistry. 
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Luxol Fast Blue-Periodic Acid Schiff’s Staining.  Paraffin-embedded sections were 
histologically stained with LFB-PAS stain as previously described (Hiremath et al. 1998).  
Myelination and cellularity are blind-scored on a scale ranging from 0 (complete 
demyelination; normal cellularity) to 3 (no demyelination; heavy accumulation of cells 
typical of 5-week cuprizone-treated wild type male C57BL/6 mouse).   
 
Immunohistochemistry and Lectin staining.  All comparative analyses were restricted to the 
midline of the corpus callosum. 
Fixed-frozen sections were thawed and washed in 0.05 M potassium phosphate 
buffered saline (KPBS).  NG2 is a chondroitin sulfate proteoglycan that is expressed by 
oligodendroglial precursor cells.  Briefly, sections were blocked and permeabilized in 2% 
NGS and 0.1% Triton X-100 in KPBS for 30 minutes and incubated in rabbit anti-NG2 
(1:500, gift from Dr. William Stallcup, Burnham Institute for Medical Research, La Jolla, 
CA) for overnight at 4°C.  Tissues were washed with KPBS and incubated with Alexa Fluor 
goat anti-rabbit IgG (1:400, Invitrogen/Molecular Probes, Carlsbad, CA).  Tissues were 
washed and mounted in Vectashield Hardset with DAPI (Vector) in order to visualize nuclei.  
Proliferation was determined by BrdU incorporation (as described above).  Briefly, sections 
were demasked with 2 M HCl treatment for 30 minutes at room temperature and washed with 
0.1M sodium tetraborate (pH 8.5, Sigma).  Tissues were then incubated with 500 Kunitz 
units/ml DNAse I (Sigma) for 30 minutes at room temperature and washed with KPBS.  
Sections were incubated with mouse anti-BrdU (1:500, Zymed) overnight at 4°C and 
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subsequently followed with Alexa Fluor goat anti-mouse IgG (1:400, Invitrogen/Molecular 
Probes).  Sections were washed and mounted as previously described above. 
For LAG-3 immunohistochemistry, fixed-frozen sections were thawed and were 
blocked in 10% NGS and 1% BSA in PBS for 1 hour.  Sections were incubated in rat 
monoclonal anti-LAG-3 (1:50, C9B7W, gift from Dr. Dario A. Vignali) for overnight at 4°C.  
Tissues were washed with PBS and incubated with biotinylated anti-rat IgG (1:100, Vector) 
for 1 hour.  Sections were then washed and incubated with Alexa Fluor streptavidin (1:400, 
Molecular Probes/Invitrogen).  Sections were washed, and lightly fixed in 2% PFA for 10 
minutes.  Again, sections were washed and co-labeled with a cell marker.  LAG-3 
immunohistochemistry was performed first and followed by the appropriate cell marker 
immunostaining protocol in this section. 
Paraffin sections were deparaffinized with Histo-Clear (National Diagnostics, 
Atlanta, GA) and rehydrated through a series of graded ethanols.  Immunohistochemistry for 
Glutathione S-Transferase pi (GSTpi) was performed to identify mature oligodendrocytes as 
described previously (Mason et al. 2000).  Briefly, tissue sections were blocked and 
permeabilized in 2% NGS and 0.1% Triton X-100 in PBS for 30 minutes at room 
temperature and then unmasked with 0.1% trypsin in a 50 mM Tris solution (pH 7.4) for 15 
minutes at 37°C.  Sections were then incubated with rabbit anti-GSTpi antibody (1:1000, 
Biotrin, USA) for overnight at 4°C.  Tissues were washed and incubated with Alexa Fluor 
goat anti-rabbit IgG (1:400, Invitrogen/Molecular Probes).  Tissues were washed and 
mounted in Vectashield HardSet with DAPI (Vector) in order to visualize nuclei.  In Situ Cell 
Death Detection, Fluorescein (Roche Applied Science, Indianapolis, IN) was used to 
determine apoptosis and used according to manufacturer’s protocol.   
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RCA-1 lectin stain was performed to identify microglia/macrophages as described 
previously (Hiremath et al. 1998).  Briefly, sections were unmasked with 0.025% protease, 
type XIV (Sigma) for 2 min at 43˚C, blocked and permeabilized with 5% bovine serum 
albumin (BSA) and 0.1% Triton X-100 in PBS, and incubated with biotinylated RCA-1 
(1:500, Vector) for overnight at 4°C.  Slides were washed and incubated with Alexa Fluor 
Strepavidin (Invitrogen/Molecular Probes).  Tissues were washed and mounted as previous 
described above.   
Immunohistochemistry for GFAP was performed to identify astrocytes as previously 
described (Hiremath et al. 1998).  Briefly, sections were blocked and permeabilized in 2% 
NGS and 0.1% Triton X-100 in PBS for 30 minutes.  Sections were incubated in rat anti-
GFAP antibody (1:400, EMD/Calbiochem, San Diego, CA) for overnight at 4°C.  Tissues 
were then washed and incubated with Alexa Fluor goat anti-rat IgG (1:400, 
Invitrogen/Molecular Probes).  Sections were washed and mounted as previously described 
above. 
Image-Pro Plus v.5.0.2.9 (Media Cybernetics, Inc., Bethesda, MD) was used to 
capture digital images and count cells per mm2.  Quantification included cells in which a 
nucleus was associated with immunohistochemical staining. 
 
Mixed glial cultures. Methods were modified from [76].  Briefly, brains were removed from 
day 2-3 old postnatal mice, followed by removal of the meninges and cerebellum.  Tissue 
was mechanically and enzymatically dissociated with 0.08 Wunsch units/ml Liberase 
Blendzyme I (Roche) in HBSS for 30 minutes at 37°C, agitating every 10 minutes.  Tissue 
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suspension was triturated with a 10 ml pipette and passed through a sterile 70-μm cell 
strainer (BD Bioscience).  Single cell suspension was brought up to 50 ml in DMEM/F12 
(Gibco) +10% FBS (Atlanta Biologicals) and centrifuged at 500 x g for 10 minutes. Cells 
were washed with HBSS two more times and resuspended in DMEM/F12 +10 FBS.  Cells 
were plated onto coverslips in a 24-well plate at 2 x 105 cells/well. 
For mitogen stimulation, cells were cultured for 6 days.  Cells were washed three 
times with HBSS and switched to serum-free medium, containing D-biotin (10 ng/ml; 
Sigma), insulin (5 μg/ml; Collaborative Research), progesterone (20 nM; Sigma), putrescine 
(100 μM; Sigma), selenium (5 ng/ml; Collaborative Research), transferrin (50 μg/ml; Sigma), 
glutamine (2 mM; Gibco), HEPES buffer (15 mM; Sigma), 3,3,5-triiodo-L-thyronine (15 
nM; Sigma), penicillin/streptomycin (100U/100 μg/ml; Gibco), and BSA (1 mg/ml; Sigma) 
in DMEM/F12 (Gibco).  Mitogens were added: PDGFAA (5 or 10 ng/ml, Sigma), bFGF (5 
or 10 ng/ml, Sigma), or IGF-1 (5 or 10 ng/ml, gift from Dr. A. Joseph D’Ercole, University 
of North Carolina at Chapel Hill).  Cells were incubated for 24 h before proliferating cell 
nuclear antigen (PCNA) and LAG-3 immunostaining. 
For LAG-3 expression, cells were cultured for 4 days.  Cells were washed three times 
with HBSS and switched to DMEM/F12 + 10% FBS + 5 ng/ml PDGF-AA.  Cells were 
incubated for 3 days, with daily media changes.  Cells were then immunostained for LAG-3 
and various cell markers. 
 
Mixed glial immunocytochemistry and MHCII tetramer binding.  Coverslips were washed 
with HBSS and lightly fixed with 2% PFA for 10 minutes.  Coverslips were washed 3 times 
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with HBSS and blocked.  LAG-3 and cell marker immunocytochemistry was performed 
similarly to that listed above, replacing PBS with HBSS.  Anti-PCNA (Chemicon) was 
performed according to manufacturer’s protocol.  PE-conjugated MHC tetramer was 
obtained from the NIH Tetramer Core Facility at Emory University (Atlanta, GA).  Tetramer 
binding was performed according to recommendations by the core facility. 
 
Statistics.  Data are expressed as mean ± SEM.  Multiple comparisons were evaluated using a 
two-tailed Student’s t-test.   p  0.05 were considered statistically significant. 
 
3.4 RESULTS 
 
LAG-3 expression increases during cuprizone treatment and peaks at full demyelination.  
Northern blot analysis of the distribution of lag-3 mRNA in mouse revealed strong 
expression in the thymus and spleen [157].  Surprisingly, there was also a significant amount 
of message in the brain which appeared to differ with the maturational state of the animal.  In 
postnatal day 7 mouse brains, lag-3 mRNA was detected in defined tracts at the base of the 
cerebellum and in the choroid plexus.  In contrast, lag-3 mRNA was detected only in areas 
outside of the cerebellum in the adult brain.  In this study, microarray data from corpus 
callosum tissue of a cuprizone time course was analyzed for lag-3 gene expression.  During 
cuprizone insult, lag-3 expression in C57BL/6 wild type mice was upregulated to 10-fold 
over baseline (untreated) at 5 weeks, when demyelination is nearly complete and cellularity 
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is highest (Figure 1A).  Concurrently with lag-3 expression, MHCII (I-Aβ) is upregulated at 
week 5 during the height of microglia accumulation while CD4 remains unchanged.  lag-3 
upregulation was corroborated by in situ hybridization that not only showed a basal level of 
lag-3 expression in untreated brain compared to lag-3 sense probe (Figure 1C and 1D) but 
also increased expression of lag-3 that was localized to the corpus callosum after 5 weeks of 
cuprizone treatment (Figure 1B).  Furthermore, Western blot analysis demonstrated two 
interesting observations: (1) low level LAG-3 protein expression in the untreated corpus 
callosum of mice that dramatically increased upon cuprizone insult to week 5 and diminished 
upon cuprizone removal during remyelination, and (2) the presence of  truncated LAG-3 (16 
kDa) is first observed after 3 weeks of cuprizone treatment that follows the trend with full-
length LAG-3 (70 kDa), peaking at full demyelination (5 weeks) and diminishing upon 
remyelination (Figure 1E).  The last observation infers the presence of the 54 kDa soluble 
fragment would exist in the interstitial fluid if it is not degraded immediately by 
metalloproteinases [261].  Unfortunately, the Western blot antibody does not recognize 
soluble LAG-3. 
 
Absence of LAG-3 exacerbates cuprizone-induced demyelination.   Regardless of the debate 
on LAG-3 as a susceptibility marker for multiple sclerosis, the dramatic increase of LAG-3 
during cuprizone insult suggests a role in demyelination.  LAG-3-/- mice were treated on 
cuprizone, along with C57BL/6 wild type mice.  8-10 week old mice were treated with a 
0.2% cuprizone diet for up to 6 weeks.  Maximum demyelination occurs after 5 weeks of 
insult, and remyelination spontaneously occurs at week 6 and continues upon the removal of 
cuprizone.  Myelination of the corpus callosum was determined by blind-scoring of LFB-
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PAS-stained tissue sections at the midline.  A scale from 0 to 3 is reflective of the relative 
ratio of myelinated fibers, which stain blue, to unmyelinated fibers, which stain pink.  A 
score of 0 represents complete demyelination at midline of the corpus callosum; a score of 3 
represents full myelination  [modified from [187]].  LAG-3-/- mice displayed accelerated 
demyelination with a score of 1.30 ± 0.41 after 3 weeks of cuprizone treatment compared to a 
score of 2.844 ± 0.03 in wild type mice (Figure 2).  By week 5 of cuprizone intoxication, 
demyelination was comparable in LAG-3-/- mice and wild type mice.  Likewise, 
remyelination progressed similarly in both strains.  These results suggest that the absence of 
LAG-3 has a substantial effect on the pathological processes induced by cuprizone insult. 
 
 Absence of LAG-3 alters GSTpi+ mature oligodendrocyte depletion during demyelination 
and repopulation during remyelination.  Several reports from our lab and collaborators have 
shown cuprizone-induced inflammation and demyelination are associated with a decrease in 
the mature oligodendrocyte population in the corpus callosum [51, 190, 211].  GSTpi  
immunohistochemistry was used to identify mature oligodendrocytes in LAG-3-/- and wild 
type mice during cuprizone-induced demyelination and remyelination.  It was not surprising 
that the number of GSTpi+ mature oligodendrocytes declined substantially compared to wild 
type by week 3 of cuprizone treatment (252.76 ± 89.09 vs. 727.09 ± 123.69/mm2, Figure 3).  
These results corroborate the accelerated demyelination displayed in the LAG-3-/- mice 
(Figure 2).  By week 5, most of the mature oligodendrocytes are depleted in both genotypes.  
Interestingly, GSTpi+ mature oligodendrocytes reappear within the demyelinated lesion of 
LAG-3-/- mice in significantly higher numbers than wild type mice at week 7 (1015.74 ± 
79.63 vs. 722.00 ± 52.27/mm2, Figure 3).  Presumably, this reappearance of oligodendrocytes 
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in the corpus callosum is responsible for remyelination.  However, an accelerated 
remyelination in the LAG-3-/- mice is not reflected by LFB-PAS (Figure 2).  This may be a 
due to a maturational state of the oligodendrocytes, in which they are expressing GSTpi but 
not yet fully matured by myelinating axons. 
 
Absence of LAG-3 increases cellularity during demyelination.  Cuprizone intoxication results 
in a significant augmentation of cellular populations, namely microglia/macrophages, 
astrocytes, and oligodendrocyte progenitors [49-51, 92, 187, 190, 211, 262].  Cellularity was 
determined by blind-scoring of LFB-PAS stained tissues at the midline of the corpus 
callosum on a scale from 0 to 3.  The score estimates the number of cells that is based on the 
density of nuclei: 0 is indicative of the number of cells in an untreated corpus callosum, 3 
reflects the heavy accumulation of cells at 5 weeks of cuprizone treatment.  Compared to 
wild type mice, LAG-3-/- mice displayed a significant increase in the number of cells after 3 
weeks of cuprizone treatment (Figure 4).  These results indicate that the recruitment and/or 
proliferation of cells are affected by LAG-3 and suggest the increase in cellularity in LAG-3-/- 
mice is not due to mature oligodendrocytes, but likely other cell types. 
 
LAG-3 colocalizes to oligodendrocyte progenitors and astrocytes in vivo.  Conventionally, 
LAG-3 has been shown to be expressed by activated T cells.  However, T cells do not play a 
significant role in the cuprizone model, with CD3+ cells peaking at 2 cells/mm2 and RAG-1-/- 
mice showing no phenotypic differences compared to wild type in response to cuprizone [49, 
93, 217].  Due to lack of T cells in the corpus callosum and high LAG-3 expression, cellular 
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localization of LAG-3 was postulated to be on glial cells.  5-week cuprizone-treated tissues 
were immunostained for LAG-3 and NG2 or GFAP for colocalization with oligodendrocyte 
progenitor cells (OPCs) and astrocytes, respectively.  LAG-3 (red) colocalized to a subset of 
NG2+ OPCs (green) (line arrow heads); however, not all NG2+ cells were LAG-3+ (Figure 
5A, B, C).  Likewise, LAG-3 (red) colocalized to a subset of GFAP+ astrocytes (green) (solid 
arrow heads); not all GFAP+ cells were LAG-3+ (Figure 5D, E, F).  LAG-3 was not 
colocalized to RCA-1+ microglia/macrophages (Figure 5G, H, I).  GSTpi+ mature 
oligodendrocytes were not colocalized with LAG-3 due to their absence at 5 weeks of 
cuprizone treatment.  This is the first report for colocalization of LAG-3 to NG2+ OPCs and 
GFAP+ astrocytes. 
 
LAG-3-/- mice show an increased accumulation of immature oligodendrocytes into the corpus 
callosum.  An accumulation and maturation of OPCs into the corpus callosum during 
demyelination results in remyelination upon cuprizone removal.  In addition to increased 
cellularity and colocalization of LAG-3 to OPCs, the rapid reappearance of mature 
oligodendrocytes into the corpus callosum of LAG-3-/- mice during remyelination warranted 
examination of OPCs during cuprizone insult.  NG2 immunohistochemistry was performed 
to identify OPCs at the midline of the corpus callosum during cuprizone insult.  NG2+ OPCs 
were first detected in the corpus callosum in significantly higher numbers as early as 2 weeks 
of cuprizone insult and maintain a larger population up to 5 weeks compared to wild type 
mice (Figure 6A).  Interestingly, the number of proliferating OPCs, as measured by BrdU 
incorporation, was not significantly different in LAG-3-/- and wild type mice (Figure 6B).  
Previous studies suggest OPC accumulation likely arose from a migration from the SVZ into 
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the corpus callosum and from a very small local endogenous population (Mason et al, 2000).  
Immunohistochemistry of NG2+ OPCs and BrdU incorporation did not show a significant 
difference in the number of overall NG2+ cells or proliferating NG2+ cells between LAG-3-/- 
and wild type mice during demyelination (Figure 6C, D).  However, there is a trend towards 
more proliferating NG2+ cells in LAG-3-/- mice at 2 weeks (166.502 ± 48.358 vs. 81 ± 8.18 
cells/mm2) (Figure 6D).  Therefore, LAG3 may be inhibiting OPC numbers in the corpus 
callosum. This is not due to the proliferation of the endogeneous population of OPCs within 
the corpus callosum but may be occurring in the SVZ where there is a trend for greater 
numbers of OPCs. 
 
Mice lacking LAG-3 show increased astrogliosis during demyelination.  Astrocytes 
accumulate in moderate numbers during cuprizone-induced demyelination and unlike 
microglia/macrophages, remain present in modest numbers throughout remyelination.  In this 
report, GFAP is used immunohistochemically as a marker for astrocytes.  LAG-3-/- mice 
demonstrate a significantly larger accumulation of GFAP+ cells after 3 weeks of cuprizone 
treatment compared to wild type (1070.845 ± 103.408 vs. 646.230 ± 49.14 cells/mm2, Figure 
7).  By 5 weeks of cuprizone treatment, astrocyte populations peak comparably in LAG-3-/-
and wild type mice (2552.98 ± 137.91 and 2604.02 ± 201.06 cells/mm2, respectively).  
During remyelination, astrogliosis begins to resolve but remains in modest and comparable 
numbers in both strains.  Thus, LAG3 on a subpopulation of astrocytes may be regulating 
astrocytes numbers that accumulate at week 3 during demyelination. 
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LAG-3-/- mice display an elevated number of microglia/macrophages during demyelination.  
During cuprizone insult, microglia/macrophages presumably accumulate within the 
demyelinating lesion to clear dying cells, such as oligodendrocytes, and debris.  Moreover, 
LAG-3 is a known ligand of MHCII, expressed by a subset of microglia/macrophages, in the 
cuprizone model [23, 93].  In this study, RCA-1 is a lectin that we used to identify 
microglia/macrophages histochemically within the corpus callosum.  LAG-3-/- mice 
demonstrate a robust microglia/macrophage response during demyelination.  By week 3 of 
cuprizone treatment, RCA-1+ microglia/macrophages accumulate to 1519.68 ± 284.52 
cells/mm2 on average compared to 754.07 ± 83.43 cells/mm2 of wild type mice (Figure 8).  
RCA-1+ microglia/macrophage populations are comparable in LAG-3-/- and wild type mice 
by 5 weeks of cuprizone treatment, when demyelination is nearly complete, and during 
remyelination.  Although LAG-3 was not colocalized to microglia (Figure 5G-I), the 
increased number of microglia at week 3 may be in response to the greater demyelination 
found in LAG-3-/- mice (Figure 2). 
 
LAG-3 expression is stimulated in proliferating cells.  LAG-3 expression has been 
characterized to activated T cells and NK cells [155].  Mixed glial cultures stimulated with 
PDGF-AA, IGF-1, or bFGF at 5 or 10 ng/ml proliferated to various levels with only 5 ng/ml 
bFGF being significant over serum-free media (Figure 9A); however, PDGF-AA at 5 and 10 
ng/ml induced the most significant amount of LAG-3-expressing cells (Figure 9B).  
Similarly, when LAG-3 and PCNA were colocalized, mixed glial cultures stimulated with 5 
and 10 ng/ml PDGF-AA exhibited the greatest amount of proliferating LAG-3+ cells (Figure 
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9C).  Subsequent preparations of mixed glial cultures will use PDGF-AA to study the OPC 
population. 
        
LAG-3 is expressed on PLP-expressing oligodendrocytes in culture.  As previously shown, 
LAG-3 is expressed in oligodendrocyte-lineage cells in vivo (Figure 5A-C).  To corroborate 
this finding, we examined LAG3 expression in our mixed glial cultures.  LAG-3 expression 
was localized to oligodendrocytes that endogenously expressed EGFP via the PLP promoter 
(Figure 5D-F).  Furthermore, we demonstrated that in our culture system at day 7, the 
majority of the PLP-expressing cells are NG2+ (Figures 5A-C).  Interestingly, LAG-3 
expression was restricted to the oligodendrocyte layer of cells (Figures 10D-F); however, the 
underlying astrocyte bed did not colocalize with LAG-3.  This could be due to the level of 
astrocyte maturity or activation state that may be terminal but would be greater in cuprizone-
treated tissues, as in Figures 5D-F.  Also, LAG-3 expression was restricted to the cell body 
and not the processes of the PLP+ oligodendrocyte cells (Figures 10D-F). 
 
LAG-3 binds MHCII tetramer in vitro.  LAG-3 on activated T cells has been previously 
demonstrated to interact with MHCII molecules [156].  We demonstrate that LAG-3-
expressing cells in mixed glial cultures bind MHCII tetramer (Figures 11A-C).  Because we 
have localized LAG-3 expression in our mixed glial cultures (Figures 5A-C), we postulate 
oligodendrocytes may bind MHCII through LAG3 on their surface. 
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3.5 DISCUSSION 
 
This study provides the first evidence demonstrating expression of LAG-3 on two 
important nonimmune cells of the central nervous system, oligodendrocyte precursor cells 
and astrocytes.  Secondly, we demonstrate LAG-3 may prevent rapid depletion of mature 
oligodendrocytes, and this is evident at week 3 where demyelination is more severe in LAG-
3-/- mice (Figure 2 and Figure 3).  Most importantly, LAG-3 may serve to inhibit OPC 
accumulation in demyelinating lesions as well as inhibit astrocyte accumulation.  Our study 
is the first to demonstrate physiological effects of LAG-3 in the central nervous system 
during demyelination and repair. 
 The association of LAG-3 with risk of MS is debatable.  The LAG-3 gene was studied 
in two independent sample sets of MS patients and healthy controls [179, 180].   Although 
the gene was reported initially to be associated with risk of MS [179], it failed to be 
replicated in an independent case-control study using a larger patient pool [180].  It must be 
noted that the lack of genetic evidence for a role in determining risk of disease does not 
preclude the potential importance for LAG-3 in MS pathogenesis.  Hence, our demonstration 
of LAG3 regulating OPCs is likely relevant to repair processes that may be hampered in 
patients with MS. 
This study evaluated the role of LAG-3 in the cuprizone intoxication model of 
demyelination and remyelination, which is characteristically a highly reproducible, acute 
CNS inflammatory model without evidence of T cell involvement [49, 93].  Because T cell 
involvement during demyelination is lacking, LAG-3 gene and protein upregulation was a 
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surprising and interesting finding (Figure 1A-E).  In situ hybridization confirmed the 
substantial increase in LAG-3 expression was localized to the corpus callosum, the site of 
acute neuroinflammation during cuprizone intoxication (Figure 1B).  Moreover, protein 
analysis by Western blot revealed that full-length LAG-3 (70 kDa) is detectable at very low 
levels in normal adult brain, upregulated early upon exposure to cuprizone, and peaks at 
week 4 through week 5 of cuprizone treatment.   
Interestingly, the cleavage product of LAG-3 proteolysis, truncated LAG-3 (16 kDa), 
was detectable as early as 3 weeks after cuprizone treatment and continued to increase and 
peak at 5 weeks, when demyelination is nearly complete (Figure 1E).  Upon remyelination, 
both full-length and truncated LAG-3 protein levels returned to baseline untreated levels.  
The presence of truncated LAG-3 infers the presence of soluble LAG-3, which would exist in 
the interstitial fluid if it is not degraded immediately by metalloproteinases [261].  Soluble 
LAG-3 (54 kDa) is the extracellular domain and does not contain the transmembrane and 
cytoplasmic domains of the full-length form [254].  LAG-3 is released in a soluble form and 
has been shown to increase after T cell activation [254].  The function of full-length LAG-3 
and sLAG-3 may be important to activation of MHCII-expressing cells [162], such as 
MHCII+ microglia within demyelinating lesions.  The presence of sLAG-3 is consistent in 
our model due to a robust inflammatory response and activation of various cell types during 
cuprizone insult.  However, because the cuprizone intoxication model lacks T cell 
participation, sLAG-3 must be released from another cell type, likely astrocytes and/or 
immature oligodendrocytes shown to express LAG-3 (Figure 5A-F).  We postulate that 
LAG-3 and sLAG-3 may be engaging MHCII+ microglia, which may be supporting 
differentiation of OPCs and remyelination based on the critical role MHCII has on 
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remyelination [23].  The mechanism for MHCII support of remyelination is currently being 
investigated. 
The expression of LAG-3 in wild type mice exposed to cuprizone correlated with 
active demyelination and mature oligodendrocyte depletion (Figure 2, 3).  However, in the 
absence of LAG-3, both processes were accelerated (Figure 2, 3).  Moreover, LAG-3-/- mice 
exhibited a significantly larger population of microglia/macrophage during 
neuroinflammation at 3 weeks (Figure 8).  This is consistent with a report that sLAG-3 
negatively regulates differentiation of monocytes into macrophages [257].  Buisson and 
colleagues propose activated LAG-3+ lymphocytes may reduce differentiation of monocytes 
in order to limit the magnitude of T-cell immune responses in a localized site of 
inflammation.    Due to absence of LAG-3, there may be a deficiency of this controlled 
differentiation in our model and, therefore, a large influx of microglia/macrophages into the 
demyelinating lesion.  With greater numbers of these microglia, a larger immune response 
may be mounted and result in accelerated demyelination.   This hypothesis could also be 
applied to the astrocyte population that have been shown occasionally to express MHCII [23] 
and is also greater in number in LAG-3-/- mice compared to wild type during demyelination at 
3 weeks (Figure 7). 
One of the most important finding in this study is the localization of LAG3 to OPCs 
both in vivo and in vitro (Figures 5 and 10).  Due to this novel finding of LAG-3 expression 
on OPCs (Figure 5A-C) and because LAG-3 is a known negative regulator of T cell 
activation and expansion [155, 175], we hypothesized that immature oligodendrocyte 
proliferation would be less restrained during cuprizone insult in the absence of LAG-3.  
Furthermore, we demonstrate that it is plausible that MHCII may bind LAG-3 on OPCs as 
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MHCII tetramers can associate with LAG-3 in vitro (Figure 11).  Microarray analysis 
demonstrated that LAG-3 expression precedes MHCII expression and peaks with nearly 
complete demyelination (Figure 3.1A).  LAG-3 expression by OPCs may be an attempt to 
slow proliferation and prepare the cell for differentiation.  Thus, LAG-3-expressing OPCs 
may be trying to find a location within the demyelinating lesion flagged by MHCII-
expressing microglia in which they can terminally differentiate.  We speculate that LAG-3 
and other factors induce terminal differentiation of the OPCs to myelinate axons.   In support 
of this, we did characterize a significantly increased number of immature oligodendrocytes in 
LAG-3-/- mice throughout demyelination compared to wild type, starting as early as 2 weeks 
after cuprizone insult (Figure 6A).  Confoundingly, this was not due to an increased number 
of proliferating OPCs.  A previous report from our lab suggests many OPCs initially migrate 
from the SVZ and fornix before accumulating in the corpus callosum during demyelination 
[198].  Upon examination of the SVZ in LAG-3-/- and wild type mice, there were no 
significant differences in the number of OPCs or proliferating OPCs (Figure 6); however, 
there is a trend of a greater number of proliferating OPCs in the SVZ at week 2 (Figure 6D).  
Alternatively, plausible explanation may be that a given snap shot, there are no differences in 
the number of proliferating OPCs; however, the rate at which proliferating cells migrate out 
of the SVZ and into the corpus callosum may be greater in the absence of LAG-3.  
Additional analyses on the OPCs within the SVZ is warranted. 
Interestingly, LAG-3 was not expressed on the oligodendrocyte processes in vitro 
(Figures 3.10D-F), suggesting OPCs must be in close cell-to-cell contact with APCs for 
LAG-3/MHCII signaling to occur.  This is consistent with the concept that, as OPCs mature, 
the extension of processes and complex arborization is indicative of differentiation.  If our 
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hypothesis that LAG-3 negatively regulates the expansion of OPCs is true, LAG-3/MHCII 
engagement would occur prior to complex arborization.  Thus, LAG-3 would most likely be 
expressed in the cell body rather than the processes.  
The astrocytes population may also express LAG-3, at least transiently.  Most 
astrocytes did not express LAG-3 in vivo and we did not detect LAG-3 expression in mixed 
glial cultures.  It is possible that astrocytes in culture had already expressed LAG-3 after 
reaching terminal numbers at the time points in which we were assessing OPCs expression of 
LAG-3.  Alternatively, proper stimulation of astrocytes may be required before LAG-3 
expression can be observed.  This will be examined in a future study.  Nonetheless, the 
detection of LAG-3 on astrocytes in vivo coupled with the increased number of astrocytes at 
week 3 in LAG-3-/- mice exposed to cuprizone suggest LAG3 may be functioning to regulate 
cell numbers. 
This study is novel in a couple of aspects: (1) it is the first physiological 
characterization of LAG-3 in the CNS during demyelination and remyelination, and (2) it is 
the first localization of LAG-3 to astrocytes and a subset of non-immune cells, immature 
oligodendrocytes.  Furthermore, our results demonstrate that LAG-3 regulates cellular 
infiltration into the corpus callosum, a site of neuroinflammation, in response to 
demyelinating insults.  Clinical approaches targeting LAG-3 should be approached carefully 
because of it dichotomous role in balancing immune responses.  
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FIGURE 3.1.  LAG-3 gene and protein expression increases in the corpus callosum during 
cuprizone-induced demyelination and decreases upon remyelination.  (A)  Affymetrix gene 
expression from the corpus callosum of wild type mice during cuprizone-induced 
demyelination at 0-6 weeks of treatment and upon remyelination at 2,4, and 6 weeks after 
cuprizone removal.  Corpus callosum was dissected from three mice for each time point.  (B-
D)  LAG-3 in situ hybridization, scale bar = 100mm:  (B) 5-week cuprizone-treated corpus 
callosum, LAG-3 antisense probe , (C)  Untreated corpus callosum, LAG-3 antisense probe,  
(D)  5-week cuprizone-treated corpus callosum, lag-3 sense probe .  (E)  LAG-3 Western blot 
of corpus callosum of wild type mice during cuprizone-induced demyelination at 0-5 weeks 
of treatment and upon remyelination at 1, 2, and 4 weeks after cuprizone removal.  Blot was 
stripped and probed for actin, which served as a loading control.  Corpus callosum was 
dissected from four mice at each time point.  
95 
 
FIGURE 3.1 
 
16 kDa 
Truncated  
LAG‐3 
96 
 
FIGURE 3.2.  LAG-3-/- mice display accelerated demyelination compared to wild type mice 
during cuprizone insult.  Mice were treated for up to six weeks (6+0), which is one week into 
remyelination.  Full demyelination is accomplished at week 5 (5+0).  6+2 means two weeks 
off cuprizone (but 3 weeks into remyelination).  Sections containing the corpus callosum at 
the level of the fornix were LFB-PAS stained, and the corpus callosum was blind-scored for 
myelination on a scale of 0 (complete demyelination) to 3 (complete myelination), with blue 
fibers indicating intact myelin.  * p < 0.002. 
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FIGURE 3.3.  LAG-3-/- mice display rapid mature oligodendrocyte depletion during 
demyelination yet accelerated mature oligodendrocyte repopulation during remyelination.  
GSTpi+ was used as a immunohistochemical marker for mature oligodendrocytes.  Positive 
cells were quantitated per mm2 in the corpus callosum.  Each bar is representative of an 
average of the data from minimum of 7 mice per genotype per time point.  * p < 0.02, ** p < 
0.005. 
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FIGURE 3.4.  LAG-3-/- mice display increased cellularity during cuprizone-induced 
demyelination compared to wild type mice.  Sections containing the corpus callosum at the 
level of the fornix were LFB-PAS stained, and the corpus callosum was blind-scored for 
cellularity on a scale of 0 (untreated, wild type cell density) to 3 (cell density typical of a 5-
week cuprizone-treated wild type mouse), with the number of nuclei indicative of the number 
of cells present. 
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FIGURE 3.5.  LAG-3 is localized to immature oligodendrocytes and astrocytes within the 
corpus callosum of 5-week cuprizone-treated wild type mice.  (A-C)  LAG-3/immature 
oligodendrocyte immunohistochemistry:  (A)  LAG-3 expressing cells were identified with 
an antibody gifted by Dr. Dario A. Vignali (red), (B)  Immature oligodendrocytes were 
identified by NG2+ staining (green), (C)  Colocalization of NG2 and LAG-3 was determined 
by overlapping immunostaining (lined arrowheads) that associated with a nucleus (DAPI, 
blue).  (D-F)  LAG-3/astrocyte immunohistochemistry:  (D)  LAG-3 expressing cells (red), 
(E)  Astrocytes were identified by GFAP+ staining (green), (F)  Colocalization of GFAP and 
LAG-3 was determined by overlapping immunostaining (solid arrowheads) that associated 
with a nucleus (DAPI, blue).  (G-I)  LAG-3/microglia/macrophage immunohistochemistry:  
(G)  LAG-3 expressing cells (red), (H)  Microglia/macrophages were identified by RCA+ 
staining (green), (I)  RCA-1 and LAG-3 did not colocalized.  Scale bar = 10μm. 
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FIGURE 3.6.  Immature oligodendrocytes infiltrate the corpus callosum in increased 
numbers in LAG-3-/- mice compared to wild type mice.  (A, C)  Immature oligodendrocytes 
were identified during demyelination using an antibody against NG2.  Positive cells in the 
corpus callosum (A) and SVZ (C) were quantitated.  Each bar in A is representative of an 
average of the results from at least 6 mice per genotype per time point.  Each bar in C is 
representative of an average of the results from 4 mice per genotype per time point.  * p < 
0.05, ** p < 0.005.  (B, D)  Proliferating immature oligodendrocytes were identified by 
colocalization of NG2 with BrdU.  Positive cells in the corpus callosum (B) and SVZ (D) 
were quantitated.  Each bar in B is representative of an average of the results from at least 6 
mice per genotype per time point.  Each bar in D is representative of an average of the results 
from 4 mice per genotype per time point.  
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 FIGURE 3.7.  Astrogliosis occurs more rapidly in LAG-3-/- mice compared to wild type mice; 
however, resolution of the astrocyte population is similar.  Astrocytes were identified during 
demyelination and remyelination using an antibody against GFAP.  Positive cells in the 
corpus callosum were quantitated.  Each bar is representative of an average of the data from 
at least 7 mice per genotype per time point.  * p < 0.002. 
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FIGURE 3.8.  Microglia/macrophages populations are significantly greater in LAG-3-/- mice 
compared to wild type during demyelination.  Microglia/macrophages were identified during 
demyelination and remyelination by the cell surface lectin, RCA-1.  Positive cells were 
quantitated in the corpus callosum.  Each bar is representative of an average of the results 
from at least 7 mice per genotype per time point.  * p < 0.02. 
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 FIGURE 3.9.  Mixed glial cultures upregulate LAG-3 expression when stimulated to 
proliferate by PDGF-AA and IGF-1.  (A)  Proliferating cells were detected by PCNA 
immunohistochemistry.  A minimum of 300 total cells per coverslip were quantitated and the 
percentage of PCNA+ cells were graphed. n=3.  (B)  LAG-3+ cells were detected by rabbit α-
LAG-3 (gift from Dr. Vignali).  A minimum of 300 total cells per coverslip were quantitated 
and the percentage of LAG-3+ cells were graphed.  n=3 .  (C)  PCNA+ LAG-3+ cells.  A 
minimum of 300 total cells per coverslip were quantitated and the percentage of double 
positive cells were graphed.  n=3. 
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FIGURE 3.10.  LAG-3 is colocalized to PLP-expressing oligodendrocytes in vitro.  (A-C)  
NG2+ cells (red) were colocalized to PLP-EGFP+ cells (green) to demonstrate the majority, if 
not all, PLP-EGFP+ cells are immature oligodendrocytes at day 7 in culture.  (D-F)  LAG-3+  
cells are colocalized to PLP-EGFP+-expressing oligodendrocytes (green). 
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FIGURE 3.11.  LAG-3+ cells bind PE-conjugated MHCII tetramer in vitro.  LAG-3 
immunohistochemistry (A, green) colocalizes with PE-conjugated MHCII tetramer (B, red) 
on day 7 of mixed glial cultures.  (C)  LAG-3/MHCII tetramer overlay. 
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CHAPTER 4 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The CNS is relatively quiescent immunologically and is a unique compartment in 
which to study immune responses when challenged by insult.  Much effort has been directed 
at identifying effector molecules that affect demyelination and remyelination for therapeutic 
utility [reviewed in [91]].  However, this effort is impeded by the fact that many effector 
molecules are shared in the progression of demyelination and remyelination, two seemingly 
opposing processes [for example, see Section 1.4: Cuprizone Studies in Genetic Knockout 
and Transgenic Mice, with particular attention to the TNF-α-/- mouse study [49] and 
Lenercept clinical trial].  Thus, elucidating the underlying molecular and cellular 
mechanisms in which these effector molecules are involved will provide insight into their 
potential as therapeutic targets in neurological diseases.  In the studies presented in this 
dissertation, we examined three effector molecules, IL-1α, IL-1β, and LAG-3, and 
demonstrate that IL-1β and LAG-3 significantly affect glial populations and that LAG-3 may 
serve in the negative regulation of OPCs and astrocytes during cuprizone intoxication. 
 
The inherent role of IL-1β in oligodendrocyte maturity.  In Chapter 2, we demonstrate that 
the absence of IL-1β negatively impacts the number of mature oligodendrocytes within the 
myelinated tract of the corpus callosum without affecting myelination.  This finding suggests 
an inherent difference in oligodendrocyte differentiation and/or maturation that is regulated 
by IL-1β.  Interestingly, progenitor and differentiated rat oligodendrocytes constitutively 
express IL-1β in vitro  and in vivo, suggesting IL-1β may fulfill a physiological role in an 
autocrine loop [129].  Incubation of differentiating rat oligodendrocytes with IL-1Ra results 
in cell death, while IL-1β does not negatively affect the survival of oligodendrocytes  [142].  
Therefore, IL-1β may be a pro-survival factor.  Based on these in vitro findings, it is not 
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surprising that IL-1β-/- mice inherently have fewer mature oligodendrocytes.  These cells may 
not survive as well during development in the absence of IL-1β, or the individual 
oligodendrocytes that do survive may be less impeded in sending processes to multiple axons 
for myelination sheath formation.  Furthermore, if there are fewer oligodendrocytes, it is 
plausible that myelinating sheaths may stretch greater internodal distances and that factors 
that dictate terminal myelination are altered in the absence of IL-1β.  The positive impact of 
IL-1β on oligodendrocyte survival or myelination makes a role for IL-1β in demyelinating 
disease unlikely, as affecting the repopulation of oligodendrocytes in a demyelinated lesion is 
not ideal.  Future studies to address this issue could be extended to IL-1RI-/- mice. 
Our finding that myelination in the absence of IL-1 is similar to that of wild type mice is 
perplexing, given the decrease in mature oligodendrocytes.  We postulate that the mature 
oligodendrocytes in the IL-1β-/- mice compensate by extending more myelinating processes 
and more effectively myelinate axons.  Preliminarily, our lab has examined mature 
oligodendrocytes in the corpus callosum of IL-1β-/- mice expressing the PLP-EGFP transgene 
and wild type controls.  We were unable to discern oligodendrocyte processes from the cell 
body due to the density of fibers and the compact nature of a healthy, fully myelinated corpus 
callosum.  Because this phenotype was restored after cuprizone-induced demyelination, 
examination of an early time point before remyelination is complete may be more 
appropriate in future attempts in discerning oligodendrocyte processes because the myelin 
tract will not be as compact.  Alternatively, sophisticated delivery of fluorescent dyes to 
single or a few mature oligodendrocytes may permit dissociation of single cell bodies and 
their processes for quantification.  Although not ideal, mixed glial cultures also may be 
utilized for examining oligodendrocyte arborization with the caveat that results may not be 
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translatable to a physiological setting. Vela et al. demonstrated higher morphological 
complexity of progenitor oligodendrocytes treated with IL-1β compared to cultures treated 
with IL-1Ra [142].  This is in contrast to our hypothesis that oligodendrocytes may extend 
more myelinating processes in the absence of IL-1β and would be interesting to note whether 
oligodendrocytes from IL-1β-/- mice display a similar phenotype in vitro.  Clearly, the role of 
IL-1β in arborization needs to be better elucidated.  Regardless of the outcomes of the 
proposed future studies, characterizing the effect of IL-1β on mature oligodendrocytes will 
elucidate a role for IL-1β in the physiological state, a field that has not yet been explored 
aside from sleep pattern studies and synaptic plasticity studies. 
 
IL-1β-/- mice differ in remyelination phenotype compared to previously published data.  A 
finding that admittedly stands out in Chapter 2 is the loss of a previously characterized 
phenotype.  In 2001, Jeffrey Mason characterized a delay in remyelination following 
cuprizone-intoxication in IL-1β-/- mice [51].  Unfortunately, our original IL-1β-/- mouse 
strain, characterized by Mason, was lost, and a new line of the same mice was re-obtained 
from Dr. David Chaplin.  The new IL-1β-/- mice, already on a C57BL/6 background, were 
backcrossed 6 generations onto our in-house C57BL/6 strain, originally from Jackson 
Laboratories, for the purpose of reliable phenotypic comparisons to wild type controls.  We 
attribute this backcrossing to the change in the remyelination phenotype based on a couple 
observations: (1) As previously mentioned in the introduction, cuprizone intoxication can 
display minor differences in time course depending on dose and, in this case, strain.  There 
have also been observations made that even within a strain, such as C57BL/6 from Jackson 
Laboratories or Charles River Laboratories, the time course of cuprizone may be altered as 
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these two sources may be susceptible to subtle genetic drift (personal communication with 
Glenn Matsushima, UNC-CH).  We examined an earlier time point at 7 weeks when 
remyelination was not complete and saw a slight trend in which IL-1β-/- mice displayed 
slightly lower remyelination (Figure 2.2).  However, upon examination by electron 
microscopy, the number of myelinated axons was similar to wild type (IL-1β-/- exhibiting 
31.5 ± 3.23 % myelinated axons and C57BL/6 exhibiting 35 ± 2.65 % myelinated axons).  A 
yet earlier time point at 6 weeks may demonstrate differences; however, we do not believe 
this will be likely.  (2) Moreover, further genetic backcrossing of IL-1β-/- mice on the 
C57BL/6 background may have eliminated genes that resulted in the altered phenotype.  
Each time a mouse with the knockout trait is crossed with a mouse of constant genetic 
background, the average percentage of the genetic material of the offspring derived from the 
constant background increases.  With sufficient backcrossing, the resulting offspring should 
differ from the constant background only by the genetic alteration.  An example in which a 
phenotypic change occurred upon backcrossing involves LTβR-/- mice.  These genetic 
knockouts originally displayed enlarged lateral ventricles following demyelination and this 
was attributed to neuronal atrophy and unresolved astrogliosis (unpublished data from Ting 
lab, UNC-CH).  Interestingly, upon further backcrossing onto the C57BL/6 background, this 
phenotype was attenuated (personal communication with Sheila Plant and Jenny Ting).  
Similarly, this may be applied to the case of the IL-1β-/- mice.  Regardless of the grounds to 
which the phenotype has changed, further backcrossing reveals a truer phenotype that we 
now report. 
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LAG-3 in the CNS.  In Chapter 3, we demonstrate the first characterization of LAG-3 
function in the brain.  Of our findings, the most significant is the localization of LAG-3 to 
NG2+ immature oligodendrocytes (OPCs).  Moreover, we report that, during CNS insult, 
LAG-3 on OPCS may interact with MHCII, as MHCII tetramers can associate with LAG-3 
in mixed glial cultures, and such an interaction in vivo may negatively regulate OPC 
proliferation, a function reported in the periphery on LAG-3+ activated T cells.  Our recent 
attempts to culture OPCs from LAG-3-/- and wild type mice and monitor proliferation or 
differentiation after stimulating with PDGF and removal of fetal calf serum were 
unsuccessful due to an inability to detect LAG-3 on wild type mixed glial cultures.  
Currently, the reagents used in the cultures and the protocol are being reexamined for 
potential changes that may result in the lack of LAG-3 expression.  
To date, we have been unable to co-localize MHCII and LAG-3 in brain tissues 
during cuprizone treatment, where both molecules have shown to be elevated by mRNA and 
protein (Figure 3.1, [23]) or in vitro using mixed glial cultures.  Results obtained from 
commercially available oligodendrocyte and monocyte/macrophage cell lines may 
additionally illustrate actual binding of the two molecules.  The caveat of cell lines is that 
many of them express cell markers that do not appear in vivo and, thus, may be misleading. 
Unfortunately, the only LAG-3 antibody that has successfully immunostained tissues is the 
same isotype as our working MHCII antibody.  Moreover, double staining has proven 
difficult, as both antigens provide weak signals and require signal amplification.  Therefore, 
better reagents will be necessary to demonstrate such LAG-3/MHCII interactions in vivo, as 
well as in vitro.  An alternative method to demonstrate LAG-3/MHCII interactions in the 
brain would be immunoprecipitation of one molecule and Western blot the other.  The caveat 
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of this method is that cellular expression of either molecule would be undeterminable, as 
LAG-3 is demonstrated on OPCs and astrocytes in Chapter 3 and MHCII has been 
demonstrated previously on microglia and, to a lesser extent, on astrocytes in the cuprizone 
model [23].   
Additionally, the negative regulation of OPCs should be more intensively studied.  
The mere presence of a significantly larger population of NG2+ cells in the corpus callosum 
as early as 2 weeks indicates increased proliferation of these cells within the brain (Figure 
3.6A).  However, this proliferation does not appear to be occurring in the corpus callosum 
(Figure 3.6B).  Based on previous studies by Jeffrey Mason that suggest many OPCs initially 
migrate from the SVZ to the fornix before accumulating in the corpus callosum led us to 
examine the SVZ for proliferating OPCs.  Our study suggests a trend of greater proliferating 
OPCs in the SVZ of LAG-3-/- mice at 2 weeks of cuprizone treatment (166.50 ± 48.36 vs. 
81.11 ± 8.18 cells/mm2).  However, this study was preliminary and based on counts from 4 
mice.  Incidentally, significance was lowered from one outlier in the LAG-3-/- mice and, when 
removed, the significance at 0.13 dramatically lowered to 0.03.  Thus, it is feasible that by 
increasing the number of tissues, a significance in proliferation may surface.  Nonetheless, 
the finding that LAG-3 may regulate OPC is a novel and important finding as few negative 
regulators of oligodendrocytes have been described.  A recent molecule identified to regulate 
oligodendrocytes is LINGO-1, which activates RhoA and reduces oligodendrocyte 
differentiation and myelination [263].  LINGO-1-/- mice have not been examined in adult 
mice during remyelination and it may be interesting to compare phenotypes in the cuprizone 
model. 
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Furthermore, the fornix should also be analyzed for OPC numbers in the LAG-3-/- 
mice.  Although from cursory observations in examining the corpus callosum and SVZ, few 
cells in the fornix appear to be BrdU+.  An interesting study that may shed light on the 
negative regulation of LAG-3 on OPCs due to MHCII interaction would be to examine BrdU 
incorporation in LAG-3-/- and wild type mixed glial cultures upon the addition of the MHCII 
tetramer or MHCII-expressing cells (microglia or CIITA-transfected BV2 cells, a microglial 
cell line).  If LAG-3 negatively regulates OPC proliferation, as it does T cells in the 
periphery, targeting LAG-3 in therapeutic applications could result in priming demyelinating 
lesions with a greater number of cells that have the capacity to remyelinate upon maturation.  
This is supported by the significantly larger population of mature oligodendrocytes during 
remyelination in LAG-3-/- (Figure 3.3).  In addition, if one considers propagating OPCs from 
stem cells or precursor cells, inhibition of LAG-3 may provide a greater yield of OPCs 
available for transplantation into demyelinated lesions which experimentally is feasible 
(Mason et al, 2004). 
The substantial influx of cells in LAG-3-/- mice during demyelination is only partially 
attributed to OPCS (Figure 3.4).  Microglia and astrocytes, cell types that contribute to the 
pro-inflammatory response, also accumulate in greater numbers in the absence of LAG-3 at 3 
weeks of cuprizone treatment (Figures 3.7 and 3.8).  This observation coincides with 
dramatic demyelination and mature oligodendrocyte depletion observed at the same time 
point (Figures 3.2, 3.3).  LAG-3 is typically associated with activation of APCs (see Section 
1.3: LAG-3: An APC Activator), so, in the absence of LAG-3, this observation was 
surprising.  However, a report by Buisson and colleagues demonstrates that sLAG-3, which 
is present during cuprizone-induced demyelination (Figure 3.1), negatively regulates 
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monocytes differentiation [257].  They propose that activated lymphocytes that express 
LAG-3 may reduce differentiation of monocytes in an attempt to limit the magnitude of T 
cell immune responses in a localized lesion during inflammation.  Thus, in the LAG-3-/- mice, 
there may be a deficiency of this controlled differentiation and, therefore, a large influx of 
macrophages and astrocytes enter the demyelinating lesion.  Moreover, in the periphery, 
deregulation of in vivo T cell homeostasis by administration of anti-Lag-3 mAb resulted in 
the expansion of several cell types that include B cells, macrophages, granulocytes, and 
dendritic cells [177].  Thus, LAG-3 may be playing a similar regulatory role in the CNS, 
albeit without T cells.  Interestingly, we demonstrated LAG-3 expression on astrocytes 
during demyelination.  It is plausible that these LAG-3+ astrocytes may take on an immune 
regulatory role in the CNS, a role occupied by T cells in the periphery, and in the absence of 
LAG-3 are unable to control cellular MHCII+ microglial expansion.  Targeting LAG-3 for 
therapy of demyelinating diseases may prove to exacerbate inflammation and demyelination.  
Thus, as stated before, careful elucidation of underlying molecular and cellular processes is 
critical in therapeutic strategies. 
Of great interest is reconciling the LAG-3-/- mouse phenotype in which demyelination 
is exacerbated and remyelination is not affected except for the slight increase in mature 
oligodendrocytes, and I-Aβ-/ - mouse phenotype in which demyelination is delayed and 
remyelination is impaired (Table 4.1) after cuprizone intoxication.  Unpublished data from 
our lab demonstrates that, despite a similar phenotype to I-Aβ-/- mice during demyelination, I-
Aβ tr mice which express I-A but is mutated in the cytoplasmic domain, show no deficit in 
remyelination and exhibit recovery similar to wild type mice.  These studies suggest that, 
while an intact MHCII molecule promotes remyelination, the absence of a signaling 
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mechanism does not delay remyelination.  The similar remyelination phenotype between 
LAG-3-/- and I-Aβ tr mice suggest that LAG-3/MHCII engagement does not require signaling 
through the MHCII-expressing microglia for remyelination to occur.  Interestingly, the slight 
increase of mature oligodendrocytes in LAG-3-/- mice at week 7 does not result in accelerated 
remyelination.  This may be a result of LAG-3 independent mechanisms that control the 
differentiation or maturation of oligodendrocytes or the rate of myelination of axons.  Thus, 
despite a larger population of mature oligodendrocytes in the absence of LAG-3, these cells 
may not receive proper cues to terminally differentiate into myelin-producing cells.  In 
contrast, I-Aβ -/- mice display a deficit in mature oligodendrocyte repopulation up to 2 weeks 
off cuprizone [23] and I-Aβ tr mice exhibit mature oligodendrocyte repopulation similar to 
wild type mice (unpublished data), suggesting that, while the absence of MHCII signaling 
does not affect oligodendrocyte repopulation, the absence of the MHCII molecule effectively 
reduces this population during remyelination.  We postulate that the MHCII molecule may 
engage (1) LAG-3-expressing OPCs to impair OPC migration through the corpus callosum 
and (2) additional unidentified molecules dependent on engaging MHCII to trigger 
myelination.  Thus, LAG-3 may discriminately regulate OPC population numbers and not 
mature oligodendrocyte populations.  Future directions include examining whether mature 
oligodendrocytes express LAG-3.     
While LAG-3 appears to attenuate demyelination, MHCII exacerbates demyelination 
[93].  LAG-3 has a 100x stronger binding affinity to MHCII compared to soluble CD4 [159, 
167, 168], and LAG-3/MHCII interactions have been postulated to complement other 
interactions, such as CD40/CD40L in T cell/DC cross talk when conditions are suboptimal 
(i.e. lack of CD40L expression on poorly activated CD4+ or CD8+ cells) [250].  We postulate 
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that in the presence of LAG-3, MHCII engagement induces MHCII signaling and 
exacerbates demyelination.  However, in the absence of LAG-3, MHCII may transiently 
engage an unknown molecule, inducing weak MHCII signaling and attenuated 
demyelination.  Despite weak signaling through MHCII in LAG-3-/- mice, with increased 
microglia/macrophage accumulation, inflammation may be elevated, resulting in exacerbated 
demyelination.  A cytokine and growth factor profile by microarray or ribonuclease 
protection assay (RPA) in wild type and LAG-3-/- mice will need to be done.  In addition to 
the negative regulatory function of LAG-3 on the cell that expresses it, we are also interested 
in the regulatory effects of LAG-3 on APCs.   Future aims are focused on in vitro studies in 
characterizing the effects of the addition of LAG-3-expressing cells (e.g. LAG-3 transfected 
CHO cells) to microglial cultures (i.e. cytokine and growth factor production).   
In light of the characterization of LAG-3-/- mice during cuprizone-induced 
demyelination and remyelination presented in Chapter 3, future studies can focus now on 
exploring the functional properties of LAG-3.  Because of the two-way signaling involved in 
LAG-3 function, avenues to explore are (1) the negative regulation of cells expressing LAG-
3 and (2) the activation of MHCII-expressing APCs to which LAG-3 binds.  In our 
demyelination and remyelination model, expression of LAG-3 on OPCs may serve to “jump 
start” remyelination.  We hypothesize that LAG-3 inhibits OPC proliferation, allowing OPCs 
to differentiate into myelin-forming cells.  This is not reflected in our results from Chapter 3 
that demonstrates LAG-3-/- mice and wild type mice remyelinate similarly with an increased 
number of mature oligodendrocytes at 7 weeks in LAG-3-/- mice.  This discrepancy may be 
due to other unknown inhibitory mediators, such as LINGO-1, or growth factors may initiate 
remyelination to compensate for the lack of LAG-3 [49, 100, 263, 264].  Furthermore, 
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negative regulation of astrocytes may be an inherent mechanism to control an overactive 
immune response, as these cells are able to produce pro-inflammatory mediators, such as 
TNF-α, LTα, and IFNγ [44, 49, 50].  Astrocytes also function as a supportive cell for 
oligodendrocytes through production of growth factors, such as IGF-1 and TNF-α [49, 51].  
Limiting their expansion may also impair OPC proliferation and influence OPCs toward 
maturation.  Lastly, activation of MHCII+ microglia, possibly through LAG-3 engagement, 
has been shown by Arnett and colleagues to be important for remyelination processes [23].  
Mechanisms to support these hypotheses need to be explored further. 
Because LAG-3 is known to be expressed on T cells, our studies also need to be 
extended to T cell-mediated models of demyelination, such as EAE or viral models of 
demyelination.  Although the cuprizone model allows the study of immune responses, the 
importance of T cell immunity in diseases, such as multiple sclerosis, should also be 
examined.  We hypothesize that the negative regulation of T cells by LAG-3 during a Th1-
mediated autoimmune response would be vital to restrict and contain damage to myelin and 
oligodendrocytes.  Contrastingly, negative regulation of OPC expansion in this scenario may 
impair remyelination unless compensatory mechanisms exist to propagate this population of 
cells.   
Multiple sclerosis is a heterogeneous disease with unclear causation and pathologic 
features that in some cases mimic T cell-mediated inflammation but, in other reports, is 
thought to be primarily an antibody-mediated disease.  Other lesions suggest primarily a 
microglial response, as Barnett and Prineas have described newly forming lesions that have 
extensive oligodendrocyte apoptosis and microglial activation in the absence of lymphocytes 
[210].  Our work in the cuprizone model reflects a primarily microglial response and our 
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studies clearly indicates LAG-3 has significant regulatory roles in the CNS, particularly upon 
insult.  It would be intriguing to examine whether LAG-3 expression in patients with 
multiple sclerosis may prevent or reduce the OPC population.  This could be examined in the 
cuprizone model under chronic exposure conditions where at week 12, remyelination that is 
typically feeble in wild type mice may be more robust in LAG-3-/- mice.  Nonetheless, our 
studies in this dissertation suggest immune mediators, such as IL-1β and LAG-3, may have 
profound effects in the pathologies of the CNS and may provide insights and considerations 
to future therapies. 
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TABLE 4.1.  Reconciliation of I-Aβ-/- and LAG-3-/- Phenotypes During Cuprizone-induced 
Demyelination and Remyelination. 
FEATURES  WILD TYPE I‐Aβ
‐/‐ [23, 93] I‐Aβ
tr [93] LAG‐3‐/‐ [Chapter 3]
MHCII‐LAG‐3 
Schematic 
   
Demyelination    Delayed Delayed Accelerated
   Mature OLs    ND ND Accelerated   
depletion 
   OPCs    ND ND Increased 
accumulation 
   Microglia/Mφ    Decreased 
accumulation 
Decreased 
accumulation 
Increased 
accumulation 
   Astrocytes    ND ND Increased 
accumulation 
Remyelination    Impaired No effect* No effect 
   Mature OLs    Decreased 
repopulation 
No effect* Accelerated 
repopulation 
   OPCs    ND No effect* No effect 
   Microglia/Mφ    ND ND No effect 
   Astrocytes    ND ND No effect 
Interpretation    Intact MHCII 
exacerbates 
demyelination 
 
Intact MHCII 
promotes 
remyelination 
MHCII signaling 
exacerbates 
demyelination 
 
MHCII signaling is 
not required for 
remyelination 
LAG‐3 attenuates 
demyelination 
 
LAG‐3/MHCII 
engagement is not 
required for 
remyelination 
Conclusions  MHCII exacerbates demyelination, presumably through microglia/macrophage 
activation.  LAG‐3 serves as a “brake” in cellular accumulation, in this case 
microglia/macrophages. 
ND = Not determined. 
* = Unpublished data. 
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